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This document derives from a series of on-going sym-
posia organized by the Canadian Centre on Substance 
Abuse (CCSA) with the support of a variety of region-
al, national and international organisations. The First 
International Symposium on Estimating the Social and 
Economic Costs of Substance Abuse was held in 
Banff, Alberta, in 1994, and the Second International 
Symposium on Estimating the Social and Economic 
Costs of Substance Abuse was held in Montibello, 
Quebec, in 1995. The first symposium focused on 
issues of economic modeling while the second sympo-
sium focused on epidemiological issues involved in 
estimating deaths, hospitalizations and crime attribut-
able to substance abuse. These meetings were orga-
nized and co-hosted by the CCSA with funding sup-
port from the following organisations: the Alcohol 
Advisory Council of New Zealand; the Addiction 
Centre, Foothills Medical Centre, Canada; the Alberta 
Alcoholism and Drug Abuse Commission; the 
Australian Department of Human Services and Health; 
Canada's Drug Strategy Secretariat of Health Canada; 
the Center for Substance Abuse Prevention, USA; the 
Foothills Hospital Foundation, Canada; The Friends of 
Matt Newell Fund, Canada; the Health Promotion 
Directorate, Alcohol and Other Drugs Programs, 
Health Canada; the International Labour 
Organization, Switzerland; the National Institute on 
Drug Abuse, USA. The financial support of these 
organizations and the expertise that individual partici-
pants brought to the meetings are gratefully acknowl-
edged. 
The first edition of the guidelines was developed by a 
working group designated by participants at these 
meetings, consisting of Eric Single (Canada, chair), 
David Collins (Australia), Brian Easton (New Zealand), 
Henrick Harwood (USA), Helen Lapsley (Australia) 
and Alan Maynard (UK). The guidelines were pub-
lished by the CCSA in 1996, and provided the basis 
for further cost estimation studies in Australia (Collins 
and Lapsley, 1995), Canada (Single et al., 1998) and 
the US (Harwood et al., 1999). The first edition of the 
guidelines have also been available at the CCSA web-
site (http://www.ccsa.ca), and were used in a number 
of other cost estimation studies in Europe and South 
America. 
The Third International Symposium on Estimating the 
Social and Economic Costs of Substance Abuse, held 
in Banff, Canada in the fall of 2000, focused on 
emerging issues in the application of the guidelines, 
particularly their utility in developing economies and 
in drug-producing countries. It was decided that a 
second edition of the guidelines should be prepared 
and an expanded working group was struck, consist-
ing of Eric Single (Canada, chair), David Collins 
(Australia), Brian Easton (New Zealand), Henrick 
Harwood (USA), Helen Lapsley (Australia), Pierre 
Kopp (France) and Ernesto Wilson (Colombia). The 
group held a 3-day working meeting in Washington, 
D.C., in May of 2001 at the offices of the Inter-
American Agency on Narcotic Drugs (CICAD) and 
finalised this second edition of the guidelines. 
As with the original guidelines, this second edition of 
the guidelines is truly a collaborative effort. The 
organisation and first sections of these guidelines are 
based in large measure on planning documents pre-
pared by Eric Single. Section 2, "A Layperson's Guide 
to the Evaluation of Social and Economic Costs of 
Substance Abuse", was prepared by Brian Easton. The 
description of a common framework for economic 
cost studies in Section 3 draws upon material from 
presentations at the three symposia, and particularly 
the paper at the first symposium by Henrick Harwood 
entitled "Selected Issues and Parameters In the Design 
and Performance of Cost-of-illness Studies for 
Substance Abuse". David Collins, Brian Easton, Helen 
Lapsley, Pierre Kopp and Eric Single also made signifi-
cant contributions to the discussion of issues in 
Section 3. The detailed discussion in Section 4 of the 
issues involved in the application of this framework, 
which also draws upon the background papers, is 
based in part on a working paper by David Collins 
and Helen Lapsley entitled "Technical Issues in Abuse 
Cost Estimation". Parts of this discussion were also 
prepared by Brian Easton, Henrick Harwood and Eric 
Single. Ernesto Wilson, David Collins, Helen Lapsley 
and Eric Single contributed to the development of 
Section 5 on data requirements in developing 
economies. The concluding sections of these guide-
lines represent a collaboration of all members of the 
Working Group. Appendix A, the "Glossary of com-
mon terms used on economic cost studies", was pre-
pared by Brian Easton and Robert Bowie. Brian Easton 
also drafted Appendix B and Appendix C with signifi-
cant input from all of the members of the working 
group. Eric Single was responsible for pulling the vari-
ous components together and editing the final text. 
Special mention should be made of Jacques LeCavalier 
for the central role he played in coordinating and 
organizing the three symposia, and for his enthusiastic 
promotion of the development of these guidelines. 
Finally, thanks are due to Maristela Monteiro, 
Coordinator, and Isidore Obot, Scientist, Management 
of Substance Dependence, Department of Mental 
Health and Substance Dependence, World Health 
Organization, for their roles in the finalization and 
publication of this document. 
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The use of alcohol, tobacco, pharmaceuticals and 
illicit drugs involves a wide variety of adverse 
health and social consequences. There is a strong 
need for improved estimates of the economic costs 
of substance abuse. Cost estimates help to priori-
tize substance abuse issues, provide useful informa-
tion for targeting programming, and identify infor-
mation gaps. The development of improved cost 
estimates also offers the potential to develop more 
complete cost-benefit analyses of policies and pro-
grammes aimed at reducing the harm associated 
with the use of psychoactive substances. 
This document presents a general framework for 
the development of cost estimates. Studies of the 
economic costs of substance abuse are described as 
a type of cost-of-illness study in which the impact 
of substance abuse on the material welfare of a 
society is estimated by examining the social costs of 
treatment, prevention, research, law enforcement 
and lost productivity plus some measure of the 
quality of life years lost, relative to a counterfactual 
scenario in which there is no substance abuse. 
A matrix of the types of costs to be considered is 
presented, and there is a detailed discussion of the 
theoretical issues involved, including: the definition 
of abuse, determination of causality, comparison of 
the demographic and human capital approaches to 
cost estimation, the treatment and measurement of 
addictive consumption, the treatment of private 
costs, the measurement of intangible costs, the 
treatment of non-workforce mortality and morbidi-
ty, the treatment of research, education, law 
enforcement costs, the estimation of avoidable 
costs and budgetary impact of substance abuse. 
Special considerations are discussed with regard to 
developing economies and drug-producing coun-
tries. The guidelines conclude with a brief discus-
sion of future directions, with particular attention to 
the expansion of economic cost studies to develop-
ing countries, and the implications of these guide-
lines to research agendas and data collection sys-
tems. 
Estimating the costs 
of substance abuse: 
introduction 
There is a strong interest in many countries 
regarding the development of scientifically valid, 
credible estimates of the economic costs of drugs, 
alcohol and tobacco. The costs of substance abuse 
represent an issue of key interest to stakeholders, 
policy makers and the media. Knowledge of the 
costs of resources associated with alcohol, tobacco 
and drug abuse informs decisions related to fund-
ing and to interventions, which are designed to 
reduce abuse. Relatively few countries have 
attempted to estimate the costs of substance 
abuse. Such estimates are fraught with method-
ological difficulties resulting in widely varying esti-
mates. 
In May 1994 an international symposium was held 
in Banff, Canada, to discuss the issues involved in 
estimating the social and economic costs of sub-
stance abuse, and to seek a consensus on the 
most appropriate model. The purpose of the 
meeting was to explore the feasibility of establish-
ing an internationally acceptable common 
methodology for estimating the costs of alcohol 
and other drugs. The symposium in Banff brought 
together persons with experience and expertise in 
dealing with the issues of costs estimation. Three 
papers were presented reviewing the current state 
of knowledge and exploring various methodologi-
cal issues. 1 
There was a general agreement that it is possible 
and desirable to develop a set of guidelines 
regarding the estimation of the costs of substance 
use and abuse. The participants at the Banff sym-
posium also agreed that the guidelines should be 
viewed as only the first step towards the develop-
ment of improved and more internationally com-
parable estimates of the social and economic costs 
of substance use and abuse. A working committee 
consisting of the Eric Single, David Collins, Brian 
Easton, Henrick Harwood, Helen Lapsley and Alan 
Maynard drafted the first set of guidelines that 
were subsequently published by the Canadian 
Centre on Substance Abuse. 
In 1995 a second symposium on estimating the 
economic costs of substance abuse was held in 
Montebello, Quebec. Whereas the first sympo-
sium had focused on modeling and methodologi-
cal issues, this symposium focused more on epi-
demiological and practical issues involved in deriv-
ing cost estimates. In 2000 a third symposium was 
held in Banff, Alberta. This symposium focused on 
the results of cost studies using the guidelines, as 
well as special considerations involved in conduct-
ing cost estimation studies in developing 
economies and in drug-producing countries. It was 
decided to expand the working group to include 
economists from Europe (Pierre Kopp) and from 
South America (Ernesto Wilson). Following a spe-
cial meeting at the offices of the Inter-American 
Agency on Narcotic Drugs (CICAD) in Washington 
in May, 2001, the following revised guidelines 
have been prepared. 
1.2 The purposes of economic cost estimates 
The need for estimates of the economic costs of 
substance abuse is almost self-evident. It is well 
established that the use of alcohol, tobacco and 
other drugs involves a large number of adverse 
health and social consequences. Thus, in most 
countries there are national policies for substance 
abuse, unlike for most other commodities. Because 
the justification for special regulation is the eco-
nomic and social costs, and also because economic 
policy instruments are used in the regulation of 
these substances, it makes good sense to have 
sound estimates of the costs of substance abuse. 
Estimates of the social and economic costs of sub-
stance abuse serve many purposes. First, economic 
cost estimates are frequently used to argue that 
policies on alcohol, tobacco and other drugs 
should be given a high priority on the public policy 
agenda. The public is entitled to a quality standard 
against which individual cost estimation studies 
can be assessed. Without such a standard there 
will be a tendency by the advocates for each social 
problem to overbid, adding in additional items to 
make their concern a suitably high (even exagger-
ated) number. 
Second, cost estimates help to appropriately target 
specific problems and policies. It is important to 
know which psychoactive substances involve the 
greatest economic costs. For example, the recent 
study by Collins and Lapsley2 concluded that the 
costs of alcohol and tobacco far exceeds the social 
costs from illicit drugs in Australia, thus focusing 
greater attention on public policy towards the licit 
drugs. Would a similar conclusion be reached in 
other countries? The specific types of cost may 
also draw our attention to specific areas which 
need public attention, or where specific measures 
may be effective. 
Third, economic cost studies help to identify infor-
mation gaps, research needs and desirable refine-
ments to national statistical reporting systems. 
Indeed, it will be argued in this report that the 
development of improved, internationally compa-
rable methods for estimating the costs of sub-
stance abuse should be attempted, insofar as pos-
sible, within the framework of the existing System 
of National Accounts (SNA). This system, which is 
best known for the Gross Domestic Product (GDP) 
measure3 of total market activity, is oriented 
towards production and market activities, and 
does not generally cover important activities which 
occur outside the market, or affect the quality of 
life, and death. Hopefully, national accounting sys-
tems could be expanded and modified to facilitate 
economic cost studies, which are concerned with 
non-market activities and mortality. The develop-
ment of estimates of the costs of substance abuse 
in the framework of the System of National 
Accounts would be a further step in the improve-
ment and refinement of national accounting sys-
tems, increasing their relevance and usefulness. 
Last but not least, the development of improved 
estimates of the costs of substance abuse offers 
the potential to provide baseline measures to 
determine the efficacy of drug policies and pro-
grammes intended to reduce the damaging conse-
quences of alcohol, tobacco and other drug use. 
Estimates of the social costs can assist policy mak-
ers in evaluating outcomes, as expressed in terms 
of changes in social costs in constant dollar terms. 
Estimates of social costs can also facilitate cross-
national comparisons of the consequences of sub-
stance abuse and different approaches to con-
fronting those consequences. Are the costs of 
alcohol consumption higher in less restrictive soci-
eties? Are the social costs of cannabis greater in 
countries where it has been decriminalised? Other 
things being equal, is there less drug abuse in 
countries where a greater proportion of the costs 
are borne by the individual? Ultimately, cost esti-
mates could be used to construct social cost func-
tions for optimal tax policy and national target set-
ting. 
Perhaps most immediately promising is the 
prospect for cost estimates to be extended to 
more comprehensive cost-benefit analyses of spe-
cific drug policies and programmes. Without a 
national (and preferably international) standard, 
individual analyses are of limited utility, because 
the results are not comparable, and their conclu-
sions can easily become dependent upon idiosyn-
cratic assumptions which the analyst has to invent. 
1.3 Organization of this report 
The following document presents the second edi-
tion of a set of international guidelines on estimat-
ing the social and economic costs of substance. 
These guidelines are subject to further revision and 
refinement as we develop greater experience and 
improved databases. The guidelines begin with a 
description of economic cost studies oriented 
toward non-economists. A detailed glossary of 
terms is attached as Appendix A. 
Section 3 presents a framework for the develop-
ment of cost estimates. The major principle under-
lying the decision regarding which costs to include 
is the robustness of the estimates, which is in turn 
dependent on the availability of data. The matrix 
of factors to consider is generally limited to costs. 
It is recommended that data on benefits be col-
lected wherever possible, and the revenue benefits 
are included in the calculation of budgetary 
impact, discussed in the next section. 
Section 4 discusses conceptual and methodological 
issues in the application of this framework. The pur-
pose is not to advocate a particular approach, but to 
describe alternatives and discuss the advantages and 
disadvantages of each approach for particular pur-
poses. The following issues are discussed: 
definition and measurement of abuse 
definition of costs 
focus on adverse consequences rather 
than consumption per se 
causality 
the demographic and human capital approaches to 
cost estimation 
treatment and measurement of addictive 
consumption 
treatment of private costs and benefits 
treatment and measurement of intangibles 
treatment of non-workforce mortality and 
morbidity 
treatment of research, education, law 
enforcement costs 
estimation of avoidable costs 
estimation of budgetary impact: 
costs and benefits to include 
Section 5 discusses special considerations for 
developing countries, outlining the key data 
requirements and prospects for closing data gaps. 
In Section 6, the interpretation of results is dis-
cussed, as well as the relevance of cost estimates 
to policy and programme development. The 
guidelines conclude in Section 7 with a brief dis-
cussion of future directions, with particular atten-
tion to the implications of these guidelines to 
research agendas and data collection systems. 
These guidelines provide a framework rather than 
a rigorous methodology to be applied in every sit-
uation. It is recognized that there will not be suffi-
cient data in many countries to implement the rec-
ommendations in this document. However, in 
many countries it will be possible to develop rea-
sonable estimates for some, if not most, of the 
costs associated with substance abuse. It is hoped 
that these guidelines will help facilitate the devel-
opment of more economic cost studies and 
enhance the comparability of such estimates. 
Although a manual providing detailed instructions 
on how to conduct cost estimation studies may be 
developed in the future, the following guidelines 
should be viewed as a general theoretical and 
methodological framework for such studies. The 
application of the guidelines in cost estimation 
studies is discussed in Appendix D. 
The guidelines are only a tentative first step in a 
process aimed at developing more reliable and 
credible estimates of the costs of substance abuse. 
The next step in this process will be to apply the 
recommended procedures in new national and 
regional studies. This in turn should lead to further 
refinements to these guidelines. The long-term 
goal is to move from cost estimation to cost effec-
tiveness analyses, and eventually to cost-benefit 
analyses of substance abuse policies and pro-
grammes. 
A layperson's guide 
to economic cost 
estimation 
Like other professions, economists rely on a sub-
stantial body of common understanding, which 
they assume in their professional communications. 
As a consequence, non-economists can be con-
fused by the writings and conversations of econo-
mists, even though these communications may be 
perfectly intelligible within the profession. This 
problem of communication with outsiders is espe-
cially unfortunate where the issue involves other 
professions, as is the case in the multidisciplinary 
field of substance abuse. 
Thus it is appropriate to begin the discussion of 
economic cost studies by elaborating for the non-
economist the implicit assumptions that the econ-
omists use. Simplification has been necessary, 
which means that some of the subtlety of the pro-
fessional discourse may be lost. Obviously then, 
this discussion cannot cover all the points in the 
guidelines, nor does it superseded them. But 
hopefully it will enable those from other profes-
sions involved with substance abuse to have a bet-
ter insight into the issues which trouble econo-
mists. 
The discussion in this section is organized around 
three interrelated topics: what economic cost stud-
ies are, what different approaches may be taken 
to estimating economic costs and what economic 
cost studies are not. 
In brief, the study of the economic costs of prob-
lems associated with the use of psychoactive sub-
stances is (1) a type of cost-of-illness study (2) in 
which the impact of substance abuse on the mate-
rial welfare of a society is estimated by examining 
(3) the social costs of resources expended for 
treatment, prevention, research and law enforce-
ment, plus (4) losses of production due to 
increased morbidity and mortality, plus (5) some 
measure for the quality of life years lost, relative 
to a counterfactual scenario in which there is no 
substance abuse. Each part of this statement bears 
elaboration. 
2.2 .1 Economic cost studies: a type of cost-of-
illness (COl) study 
The evaluation of the economic and social costs of 
substance abuse belongs to the genre of cost-of-
illness studies (COl). Superficially a COl study 
involves combining an epidemiological database 
with financial information to generate an amount 
valued in monetary terms which purports to say 
something about the costs to society of a particu-
lar disease. Typically the magnitude is large, or 
large enough, to be used to draw attention to the 
condition as one to which policy makers, research 
funders, and researchers, ought to pay attention. 
It will be clear from the intensity in which econo-
mists debate each calculation, that they have in 
mind some conceptual framework. The total is not 
just some gee-whiz figure designed to give a sig-
nificant place to this or that illness in the public 
debate. So what are economists think they are 
doing? Moreover, why do they disagree? 
At the heart of the economist's approach is that all 
relevant costs are opportunity costs, as it is the 
case when an activity (such as an illness) prevents 
resources being used for some other purpose, and 
so an opportunity is forgone. Thus COl studies 
rest on the proposition that if the illness were not 
to exist, then the resources that a society uses for 
treatment and other related purposes could be 
deployed in some other way. 
Sitting behind the opportunity cost is a counter-
factual scenario, that is, a description of an alter-
native state of affairs, by which the opportunity 
cost would be assessed. Often the counterfactual 
proposition is not controversial. For instance we 
might assume in a COl study of some viral infec-
tion, that the alternative scenario was no viral 
infection. 
In the substance abuse field the alternative can be 
more arguable. For instance, the counterfactual to 
a situation of alcohol abuse might be that the 
abusers switch their consumption to mineral water 
and other health enhancing commodities, or it 
might be that abusers switch their consumption to 
narcotics. The latter is an extreme example, and 
usually a COl study assumes a switch to non-
damaging activities, but sometimes the specific 
counterfactual situation is unclear. 
Apart from disputes over the most appropriate 
counterfactual proposition, there are also disagree-
ments that arise over what should or should not 
be included as a cost, as well as how that cost is 
to be valued or measured. These differences do 
not arise because of different underlying funda-
mental frameworks, but because the common 
framework has been applied in different ways, so 
practical considerations have led to the treatment 
of the same issue in different ways. 
This is true for COl studies. The fundamental 
framework is "value theory", the role and inter-
pretation of market price, which has been devel-
oped rigorously over the post-war period. Two 
practical applications of that theory are (1) in the 
System of National Accounts (SNA) and (2) cost-
benefit analysis (CBA), which is a method of eval-
uation of alternative actions or treatments. 
An integral assumption of value theory is that con-
sumers value their own consumption, and that 
they rationally seek to maximize the value of their 
consumption as best they can, subject to various 
limitations such as their income and borrowing 
power. Thus, it is assumed that when a person 
buys a potato, a beer or an illicit drug, the cost of 
the purchase is offset by the benefits the con-
sumer obtains from its use. Many who are knowl-
edgeable about alcohol, tobacco and drug depen-
dence would challenge the veracity of this 
assumption. Addictive behaviour seems to violate 
the assumption of rational consumer behaviour. 
How then is the economic analysis to deal with 
this situation? 
One approach is to treat the psychoactive sub-
stances as conventional commodities, assuming 
that even dependent users are consuming rational-
ly, according to their lights if not that of wiser 
counsel. In this case the perceived benefits of con-
sumption exceed the outlay on the substance, and 
the transaction is treated as rational, just as pur-
chases of other commodities, such as potatoes. 
Collins and Lapsley4 offer another approach, 
which attempts to modify the assumption of ratio-
nal consumer behaviour in value theory, without 
destroying the entire paradigm. They estimate a 
proportion of drug consumption which is judged 
to be excessive. For that portion of consumption, 
they treat drug expenditure by users as zero under 
the counterfactual scenario in which there is no 
drug abuse, on the basis that dependent users 
receive no benefit from use. (Indeed, many users 
wish they had never taken up drug use.) This per-
mits them to count expenditures on drugs by 
dependent users as a cost in the current actual 
scenario. This is a plausible alternative, which does 
not undermine value theory, although it leaves the 
difficult task of determining what proportion of 
substance use is dependent use. 
The problem of how to resolve addictive con-
sumption with the assumption of rational con-
sumer behaviour is not fully resolved. The key 
point for the non-economist is that a main objec-
tive of the economist's approach in economic cost 
studies is to retain the well-established value theo-
ry paradigm, but to adapt it for the consumer 
behaviour which addiction implies. 
2.2.2 Costs to whom? - cost studies in the 
System of National Accounts framework 
Newspaper stories often cite "costs" of various 
social problems or negative events, such as the 
loss of a business convention, the impact of poor 
weather on tourism or the dire economic conse-
quences of a professional sports strike. Frequently, 
such estimates lack credibility, as costs are magni-
fied by following the flow of dollars from one 
party to the next, with little or no consideration of 
alternative uses for the money. For example, the 
money spent by a tourist or baseball fan at a 
restaurant is counted, then the money spent by 
the restaurant to food wholesalers, then the 
farmer's income, as well as income and other taxes 
paid by workers at each stage, and so forth. The 
fact that the money spent by local residents could 
have been used for alternative purposes is not 
considered. It is not surprising that cost figures 
such as these are viewed with scepticism. A cost 
for one person is typically a benefit to another. To 
the business manager who no longer has to pay 
for his or her staff to attend the cancelled confer-
ence, to the potential tourists who stayed at home 
and to the baseball fan whose game was cancelled 
by a strike, the "costs" of these cancelled events 
are really savings. 
In short, to be credible, estimates of th~ costs of 
substance abuse must be clear with regard to 
what constitutes a cost, who bears these costs, 
and the boundaries which should be placed on the 
economic ramifications of negative impacts. 
Cost-of-illness studies are quite precise in this 
regard: they estimate the impact of illness on a 
measure of material welfare in a society, closely 
related to the Gross Domestic Product. The GDP is 
generated in the System of National Accounts 
(SNA) by combining expenditure and production 
data with accounting information to produce an 
aggregate statistic valued in monetary terms. The 
Gross Domestic Product is not an arbitrary set of 
decisions about what is to be included and how 
each item is to be valued. Rather the aim is to 
encompass all market transactions valuing them at 
their marginal private value (or utility), which is 
usually equal to the market price (including indirect 
taxes). An increase of so many monetary units in 
the GDP can be interpreted as an increase in the 
sum of consumer utility of the same amount of 
monetary units. 
In order to appreciate the significance of COl esti-
mates in this framework, consider the counterfac-
tual situation where people choose not to eat 
potatoes, but switch their expenditure to other 
products (say pasta). Clearly there will be a disrup-
tion among potato producers, but this will be off-
set by an expansion of pasta production. We take 
these two effects as (largely) balancing out, in 
which case there will be no change in GDP, even 
though there is a change in the composition of 
GDP. 
What, we might ask, is the cost-of-potatoes to the 
economy? An answer might be that it is the cost of 
production and distribution. However, this is offset 
by the benefits to consumers of eating potatoes. 
More formally, we see that in the counterfactual 
situation, where there are no potatoes (but there is 
more pasta), there is no change to GDP. So we 
assess the social cost-of-potatoes to be zero. Note 
that we are not here assuming that the cost of 
potatoes is zero to consumers. They are a real cost 
to them but it is assumed to be offset by the bene-
fits to them of the potatoes, and which is taken 
into account when they make the (private) deci-
sion to buy them. 
2.2.3 What constitutes a cost?- social vs. private 
costs 
Thus, where the costs of a commodity are largely 
limited to private costs, the economic impact is 
estimated at approximately zero. None of this 
should appear extraordinary. What is unusual is 
when we consider the same situation as it applies 
to psychoactive substances, which carries social 
costs as well as private costs. 
To simplify, we shall illustrate the argument with 
tobacco, because it is probably the simplest of all 
the drugs, and its economic impact is the most 
transparent.S This time our counterfactual scenario 
is that there is no tobacco consumption, and there 
has been none in the past, so that smokers switch 
their consumption to some standard commodities 
(such as potatoes). In effect we are assuming that 
tobacco was never introduced to the society under 
consideration, and that potential smokers did not 
choose another drug (such as cannabis). 
At first it might appear that this story was no dif-
ferent from the one about potatoes. But tobacco 
generates ill health, which requires medical care. 
The lack of smoking would mean that a significant 
quantity of medical resources would no longer be 
needed for the care of smoking induced sickness, 
and could be used for some other purposes. (It 
would also result in other savings, such as the cost 
of cleaning up litter and the costs of smoking-
related fires.) The counterfactual is a little vague 
on what exactly is the alternative, but in the con-
text it is not likely to matter. What is critical here is 
that we have a resource use consequent on the 
smoking, which is not being offset by some bene-
fit to smokers when they decided to smoke. 
The terminology that is being used here may differ 
somewhat from that used in some of the econom-
ic literature on the subject. In normal economic 
terminology, social costs generally equal private 
decision costs plus external costs. Private decision 
costs refer to the costs taken into account by the 
individuals making consumption decisions. (We 
use the term private decision costs here rather 
than simply private costs to avoid confusion with 
the distinction between private vs. public costs.) 
External costs (or externalities) refer to those costs 
that are external to the individual making the con-
sumption decision, such as the costs that smoking 
causes to non-smokers. The inclusion of such 
externalities as part of social costs is uncontrover-
sial. Indeed, external costs generally constitute vir-
tually all of the total social costs in economic 
analyses because private decision costs are usually 
offset by private benefits. In the case of substance 
abuse, however, the situation is complicated by 
the fact that much of the private decision costs 
involves addictive consumption where the 
assumption that there are offsetting private bene-
fits is subject to question. In addition to the con-
sumers bearing the cost of the consumption deci-
sion themselves, a private decision cost must gen-
erally involve a rational decision by a fully 
informed consumer. This is questionable in the 
case of a dependent consumer. Also, many of the 
costs that might be thought of as private are actu-
ally redistributed throughout a household, a com-
munity and society through a variety of mecha-
nisms and institutions. Thus, a case can be made 
that at least some of the private decision costs 
involved in the consumption of psychoactive sub-
stances are not offset by private benefits, and can 
therefore be included as part of the social costs of 
substance abuse. In sum, there is a theoretical dif-
ference between social and external costs, but in 
most economic analyses, external costs constitute 
all or virtually all of the social costs. In the case of 
substance abuse, most of the costs are generally 
also external costs, but there is some justification 
to include some private decision costs as well. 
Why is so much attention paid to the distinction 
between private and social costs and benefits? As 
the Australian Productivity Commission report on 
gambling states (1999, p. 43), it is not because 
private costs are unimportant. In fact, often they 
are far more significant than the social benefits 
and costs of an activity. Rather, private costs gen-
erally do not justify government action on the 
basis that: 
individual actions based on adequately informed 
and rational decision-making will generally 
accord with the best interests of the individual 
concerned; 
if there are no impacts on other people resulting 
from these actions which are not accounted for, 
then what is in the individual's best interests will 
also be best for society; and 
if this is the case, there is no way that govern-
ments could intervene in individuals' decisions 
that would improve the welfare of either the 
individuals concerned or society more broadly 
(Australian Productivity Commission, 1999). 
Thus the existence of private benefits and costs 
does not normally provide a justification for gov-
ernment intervention, unless the distribution of 
private benefits and costs is seen to be in conflict 
with society's concept of fairness. It can be argued 
that if lack of fairness is a problem it would be 
more efficient for the government intervention to 
take the form of broad social security or tax mea-
sures rather than measures targeted specifically at 
the activity under review. It may, however, be that 
a particular public sector intervention designed to 
reduce external costs will influence the size and 
distribution of private benefits and costs. In these 
circumstances public policy should not ignore pri-
vate benefits and costs. 
The key distinction appears to be between the pri-
vate costs which rational and fully informed smok-
ers incur by their own activities, and the social 
costs which are borne by others. However, the dis-
tinction is in reality more complex than this. 
Consider the case of a substance abuser, say a 
smoker. Conventional economic analysis of con-
sumer behaviour assumes that rational consumers 
will undertake an activity only if the private bene-
fits received at least equal the private costs of that 
activity, so that there is almost certainly a positive 
net benefit in the form of what is known as "con-
sumer surplus" (the difference between what con-
sumers would be willing to pay for a good or ser-
vice and the market price that they are actually 
required to pay). Consumers are better off, in their 
own estimation, as a result of the consumption 
activity. 
But this analysis refers quite specifically to the 
costs as perceived by the consumer. What if con-
sumers (say smokers) are uninformed or misin-
formed as to the costs which the consumption 
imposes on them? For example, smokers may not 
be aware of the full health consequences of smok-
ing (perhaps as a result of ignorance or of misin-
formation resulting from advertising) or they may 
not realise that the highly addictive nature of nico-
tine means that quitting will turn out to be much 
more difficult than they expected. 
If the smokers' actions are determined by per-
ceived costs that are less than their actual costs, 
the difference between the two is a social cost 
even though it is borne by the smokers them-
selves. This is because the smokers have not 
adjusted their behaviour in response to these 
unperceived costs and so these costs are unac-
counted for. The smokers are not necessarily 
behaving irrationally. They are simply adjusting 
their behaviour to the best available, relevant 
information. It must be emphasised that costs 
borne by the substance abusers themselves can 
represent social costs if these costs have not been 
knowingly incurred. 
It is sometimes suggested that these types of 
study should also estimate the extra value to the 
abusers (for example, the perceived benefits to 
smokers of smoking) over and above the costs to 
them of that activity, and that these net private 
benefits should be set off against the social costs. 
However, from the point of view of public policy, 
it is social costs that are relevant, not private costs. 
In determining the appropriate levels for society of 
any activity, government is interested in the costs 
that this activity imposes on the rest of the com-
munity. As an illustration, in determining the 
appropriate levels of activities such as pollution, 
environmental degradation or even violence, soci-
ety does not take into account any private benefits 
that the perpetrators may enjoy. They are seen as 
being irrelevant to the interests of the community 
as a whole. In the same way, studies of the social 
costs of substance abuse should estimate only the 
net social costs. 
In COl studies, only the social costs are consid-
ered. Some of the medical costs may fall upon the 
smoker if, e.g., there is a co-payment for public 
care or if smokers pay higher medical insurance 
premiums. Other institutional arrangements may 
require similar careful distinctions between the 
payments the smoker contributes to medical care 
(and other expenses) and the payments from 
other sources. These costs are not part of the 
costs-of-illness, but a part of the private costs 
borne by smokers, just as they pay the costs of 
their cigarettes. 
Social costs may be incurred by other persons in 
the private sector (e.g., when private insurance 
premiums are increased due to payouts to smok-
ers) as well as by public sector expenditure. Thus, 
in the context of COl studies, "social" is not a 
synonym for "public", nor "private" for "private 
sector". 
Another issue which arises in relation to drug 
abuse, is whether costs imposed by abusers upon 
other members of their own family constitute pri-
vate costs or social costs. On the one hand, it is 
argued (or asserted) that potential substance 
abusers will take into account the effects on other 
family members in deciding the extent of their 
substance abuse and that these costs are, there-
fore, internalised as private costs. On the other 
hand, how can we ignore the costs of substance 
abuse upon other people who have had no part in 
the initial decision and who may find the effects 
intolerable (for example, victims of family violence 
resulting from substance misuse) ? The size of 
abuse cost estimates will depend very significantly 
on whether family costs are treated as social costs. 
Practical questions will also arise about what con-
stitutes a family member- de facto spouses, same 
sex partners, in-laws etc. It is, in fact, difficult to 
believe that the effects of substance abuse on 
other family members should be considered to be 
solely private costs. 
Measuring the social costs of substance abuse is 
no easy matter. There is strong evidence, for 
example, that the consumption of alcohol is relat-
ed to a variety of health consequences. The prob-
ability and severity of adverse health effects of 
alcohol are strongly related to level of intake, 
often in a non-linear fashion and sometimes in a 
manner which is also situation dependent (as with 
regard to accidents). The dose-response relation-
ship is most evident with respect to cirrhosis of the 
liver, but adverse effects of high intake of alcohol 
have also been found for many other disorders 
including delirium tremens, impaired brain func-
tion, cancer of the oesophagus and digestive tract, 
chronic calcifying pancreatitis and congenital 
defects in the foetus among pregnant women. 
High and even moderate alcohol use is also associ-
ated with increased risk of trauma, such as that 
caused by impaired driving accidents. 
The proportion of each of these causes of morbidi-
ty and mortality which can be attributed to alcohol 
use must be estimated, ideally for different age 
and gender groups. Where large-scale population 
based epidemiological studies have established the 
relative risk of particular disorders at different lev-
els of alcohol consumption, the attributed fractions 
of alcohol-related morbidity and mortality can be 
determined with a fair degree of confidence. In 
many situations, however, such studies are lacking, 
and one is forced to estimate the attributable frac-
tions from less reliable sources, such as studies of 
the excess morbidity and mortality among clinical 
populations. In such cases, one is forced to make 
the dubious assumption that rates of morbidity 
and mortality in the general population of heavy 
alcohol users can be estimated from clinical popu-
lations. 
For other adverse consequences of alcohol use, 
the issue of causality can be even more daunting. 
For example, consider a person who consumed 
alcohol prior to committing a crime. Even if this 
person had been intoxicated, it is not clear 
whether the crime can be attributed to alcohol 
consumption. The alcohol may have caused the 
person to become aggressive or less inhibited, or 
precipitated the crime in some other fashion. On 
the other hand, the person may simply have hap-
pened to have a few drinks before engaging in a 
crime which he or she would have committed any-
way. Alternatively, the person may have already 
decided to commit the crime and used the alcohol 
"for courage". Thus, even when drinking immedi-
ately precedes a criminal act, the attribution of 
alcohol as a causal factor in the crime is not at all 
clear. 
Furthermore, the attributable fractions for each 
disorder vary between societies and within soci-
eties over time, so no one set of attributable frac-
tions can be applied to all societies. Thus, the 
assignment of medical costs associated with 
adverse health consequences arising from the use 
of a particular substance such as alcohol is a very 
complicated and difficult task. 
2.2.4 Further costs: productivity losses 
The reduction in medical expenses in the counter-
factual scenario is not the only important change 
as far as GDP is concerned. Total production may 
be increased because the former substance 
abusers are more productive at work, with lower 
morbidity and lower absenteeism. This additional 
production under the counterfactual scenario is 
the productivity loss from substance abuse in the 
actual situation. 6 
It is possible that to a certain extent, smokers may 
carry the burden of the lost production them-
selves, e.g. in lower remuneration. In practice, 
however, it seems unlikely that the entire burden 
of the productivity loss is carried by the smoker, 
and that at least some is carried by the employer 
in lower profits, by other employees in lower 
wages, and/or by the taxpayer in lower tax 
receipts. These losses are a part of the COl. 
2.2.5 The ultimate cost: placing a value on life 
itself 
There is one further major difference between the 
actual situation and that of the counterfactual 
which factors into economic cost studies. 
Substance use and abuse may cause death. 
Compared to the counterfactual scenario, the pop-
ulation is less. The resulting lower production 
should be included as part of the COl, by consid-
ering the loss of income due to premature mortali-
ty. 
But what are we to do about the deaths of those 
who are not in the workforce, such as homemak-
ers and the retired? It is insufficient to ignore this 
loss of life due to substance abuse. There must be 
an explicit recognition of the different life years 
experienced under the two scenarios. As discussed 
in Section 4, a dollar value can be assigned to the 
labour of persons outside of the workforce, and in 
the case of retired persons, some measure of the 
value of life years lost must be assigned. Better still 
life years should be adjusted for the quality of the 
living experience. Someone suffering from terminal 
cancer is not experiencing the same quality of life 
as their non-smoking equivalent who is leading a 
full life. 
It is not easy to value these life years or quality 
life years (QALYs). Insofar as this is an appropri-
ate thing to do, the difference between the actual 
situation and counterfactual scenario is a part of 
the COl. 
The notion of placing a dollar value on human life 
is troublesome to many. Some cultures and religions 
could not contemplate doing so. What right have 
economists to place a dollar value on life? 
Unfortunately, when it comes to policy advice, an 
economist cannot always avoid putting some 
value on life. Consider the question of whether to 
install traffic lights at a crossroad, one of which 
effect would be to reduce accidents which lead to 
deaths. If the evaluation ignored lives saved by the 
lights, that would be equivalent to treating the 
value of life as zero. As a result some life saving 
traffic systems would not be recommended. On 
the other hand if the value of life was set as infini-
ty, every traffic system which reduced the proba-
bility of death, no matter how small that probabili-
ty, would be installed, with the result that we 
could barely move given the density of life saving 
traffic lights. 
So in practice we incorporate some value of lives 
saved, when we make policy decisions, even if a 
dollar value is not stated. All economists are doing 
explicitly is what others, policy advisers and policy 
makers do implicitly. 
The issue of placing a value on human life cannot 
be avoided by ignoring the issue, for that would 
be equivalent to setting the value of life at zero. 
However, because economic cost studies do not 
strictly offer policy advice, they can avoid the issue 
by enumerating the number of years of life lost 
due to premature mortality without placing a dol-
lar value on those years. For example, the result 
might be reported that the annual cost of a partic-
ular illness was US$ 100 million plus 10,000 quali-
ty life years lost. That meaning would be that 
under the counterfactual scenario, there would be 
US$ 100 million of extra resources for consump-
tion, and 10,000 additional quality life years 
saved. 
However the cost of another illness might be US$ 
50 million plus 20,000 quality life years. Some 
may wonder which illness is the more costly, a 
question that can only be answered by combining 
the dollars with the quality life years in some way. 
Whatever way would be equivalent to putting a 
value on life? 
Another difficulty is that it is not clear that all life 
should be treated equally. This is especially perti-
nent in the context of substance abuse. Does the 
life of a chronically unemployed drunk driver have 
the same value as that of a young victim killed by 
the drunk driver? Does the life of a junkie have 
the same value as that of a productive, law-abid-
ing citizen? The question of valuing the life of the 
junkie, compared to a good citizen, may turn out 
to be trivial, providing the counterfactual is kept 
mind. Suppose the counterfactual is to eliminate 
the substance abuse. Then the counterfactual sce-
nario has the junkie as a good citizen, and her or 
his death is just as great a loss to society. 
Alternatively one might want to say the loss of the 
junkie's life is much less valuable than that of the 
good citizen, because the quality of life is lower. 
But, in addition, the counterfactual scenario is 
about the recovery of that low quality life to a 
standard one. Thus the total valuation, summing 
the two components, will be the same as the loss 
of the good citizen's life. The COl study includes 
the value of the existing damage to the life of an 
addict, as well as mortality effects. 
There are two different approaches to the estima-
tion of the economic costs of substance abuse: the 
more widely adopted "human capital" approach 
and the more recent "demographic" approach. 
The key difference, discussed in detail in Section 3, 
concerns the manner in which the costs of prema-
ture mortality are treated. In the human capital 
approach, the lost value of a deceased worker's 
production is estimated by present earnings plus a 
discounted rate of future earnings. The demo-
graphic approach compares the actual population 
size and structure to that of an "otherwise 
healthy" population, i.e. an alternative population 
in which there were no drug-related deaths. 
The key point is that these different approaches 
are complementary rather than contradictory. The 
demographic approach addresses the question: 
"Suppose there had never been any substance 
abuse or problems associated with the use of psy-
choactive substances?" The human capital 
approach addresses the question: "Suppose all 
substance abuse and problems associated with the 
use of psychoactive substances were to end 
today?" The human capital approach generates an 
estimate of the present and future costs due to 
drug-related mortality in the current year, while 
the demographic approach estimates the present 
costs of drug-related mortality in past and present 
years. 
Because these two alternative approaches to the 
estimation of the economic costs of substance 
abuse address different questions, it should not be 
expected that they would arrive at the same 
answers in all circumstances. During a period of 
increasing or decreasing consumption, one would 
expect somewhat different results. It is only during 
a prolonged period of stable consumption with no 
major impact from treatment or prevention pro-
gramming that one would expect to achieve 
equivalent results. 
Thus, there is no need to reconcile the two 
approaches. The need is to be clear about their 
origins and significance. The choice depends on 
the counterfactual situation being addressed. The 
preferred procedure will often be to conduct eco-
nomic cost studies which utilize both the demo-
graphic and human capital approach, and compare 
the results. 8 
Estimates of the economic costs of substance 
abuse may be either prevalence-based or inci-
dence-based. Prevalence-based studies estimate 
the number of cases of death and hospitalisations 
attributable to substance abuse in a given year 
and then estimate the costs that flow from those 
deaths or hospitalisations (as well as other costs, 
such as prevention, research and law enforcement 
costs). Incidence-based studies estimate the num-
ber of new cases of death or hospitalisation in a 
given year and apply a lifetime cost estimate to 
these new cases. Thus, prevalence-based estimates 
generally measure the costs of substance abuse in 
the present and the past in a given year, while 
incidence-based studies generally estimate the 
present and future costs of substance abuse in a 
given year. For ongoing health and social problems 
such as illicit drug use, the results of prevalence-
based and incidence-based estimates are often 
similar. For health problems that are declining in 
magnitude (such as smoking in some countries), 
prevalence-based estimates will generally be high-
er than incidence-based estimates. For emerging 
health issues such as epidemics of HIV or Hepatitis 
infection, incidence-based estimates generally pro-
vide higher estimates than prevalence-based esti-
mates, because many infected persons may still be 
in the latency phase of the diseases. The use of 
prevalence-based vs. incidence-based estimates is 
discussed in Section 3.11. 
Part of the appeal and desire for economic cost esti-
mates of alcohol, tobacco and other drugs may 
unfortunately be based on confusion with other 
types of economic analyses. While useful and rele-
vant to policy decisions, COl studies are not studies 
of avoidable costs, they are not studies of budgetary 
impact nor are they cost-benefit analyses. 
First, economic cost estimates do not indicate the 
amount of money and life years which could real-
istically be saved via effective government and 
social policy and programming. The counterfactual 
situation in economic cost studies is one in which 
there are no problems associated with the use of 
psychoactive substances. This counterfactual situa-
tion is hypothetical and generally not realizable 
under any circumstances. The estimated costs 
include both avoidable and unavoidable costs. 
Even if completely effective policies could be 
found with no appreciable costs for enforcement, 
treatment and prevention programming, imple-
mentation would not be instantaneous and there 
would still be lingering adverse consequences from 
past use of the psychoactive substances. The cal-
culation of avoidable costs associated with the use 
of psychoactive substances is discussed in Section 
3. 
Second, economic cost studies are not studies of 
the budgetary impact of alcohol, tobacco and 
other drugs on governments. The costs included in 
COl studies are in reference to the whole of soci-
ety and not just to the government accounts. A 
study of the economic costs of substance abuse 
would be very useful in conducting an accounting 
of the budgetary impact of psychoactive sub-
stances, as it would provide estimates for many of 
the government outlays. However, government 
costs do not include all of the costs imposed on 
the community. Further, budget impact includes 
consideration of government revenues and other 
benefits, which are not part of COl studies. The 
relationship between economic cost studies and 
estimates of budgetary impact is discussed further 
in Section 3.14. 
Finally, economic cost studies do not attempt to 
fully consider the economic benefits of alcohol, 
tobacco and other drugs, and they should not be 
confused with cost-benefit or cost effectiveness 
analyses. These are two in a range of a range of 
tools that economists and others use to evaluate 
policy proposals. In the medical area they are fre-
quently used to evaluate the usefulness of costly 
treatments or policy proposals (such as prohibiting 
drinking in certain circumstances) by, for example, 
weighing the costs of interventions against their 
benefits. 
Cost-benefit analysis is based on the same value 
theory as COl studies, and economic cost studies 
can be used to provide important cost compo-
nents in a cost-benefit analysis. However there are 
slightly different assumptions which means that 
cost-benefit analysis may give different outcomes 
and estimates. The most important differences 
involve the counterfactual scenario, and the treat-
ment of the non-market sector. 
Typically the cost-benefit analysis asks what would 
happen if the costs associated with a particular 
behaviour - such as tobacco smoking - were to 
cease from today. This contrasts with the counter-
factual scenario in a COl study, which is to ask 
what would happen if the smoking had never 
started. Even if all smoking were to stop instantly 
there would still be the consequences of past 
smoking on mortality, morbidity, and health care. 
For instance the public sector would still be 
required to provide assistance for those who 
smoked in the past and were in need of medical 
care.9 Such social costs are unavoidable, and so 
are not included as a cost in the typical cost-bene-
fit analysis. 10 
The other major difference between cost-benefit 
analyses and economic cost studies utilizing the 
SNA framework is that cost-benefit analysis has 
been concerned with the impact of an event on 
non-market activities. For instance, if the a prob-
lem of substance abuse involves keeping patients 
in hospital beds, and a counterfactual scenario of 
returning them to the community, the cost-benefit 
analysis usually includes the extra unpaid work 
that might be involved in the second scenario (as 
when extra house and care work is imposed on 
family members). 
The extension of economic cost studies to cover 
such unpaid and non-market activities does not 
represent a major difficulty in principle, but it has 
not been given priority in development. If eco-
nomic cost studies were extended to include 
unpaid and non-market activities and if they were 
able to distinguish avoidable from unavoidable 
costs, it would be enormously helpful for those 
who wish to carry out cost-benefit analyses of 
alcohol and other drug policies and programmes. 
For an economic cost estimate is almost the bene-
fit side of a cost-benefit analysis, and if done 
properly it could be readily adapted into the full 
benefit side. 11 The reason why the COl study is 
close to the benefit side of a cost-benefit analysis 
is that the avoidable costs associated with the use 
of psychoactive substances represent the benefits 
(i.e. negative cost) in a cost-benefit analysis con-
trasting the current situation with a counterfactual 
situation in which a policy or programme is intro-
duced. Thus there are potentially strong practical 
advantages to integrating economic cost studies 
with cost-benefit analyses. 
Thus economic cost studies, while based on the 
same value theory, involve differences with cost-
benefit analysis. Some of those differences can be 
eliminated with development. There is no ultimate 
reason why the economic cost studies in the SNA 
framework should ignore non-market activities. 
Experience derived from cost-benefit analyses in 
dealing with non-market activities and estimating 
avoidable costs will hopefully inform the further 
development of economic cost estimates in the 
SNA framework. 
Finally, it should also be noted that COl studies, 
like most forms of economic analyses, only con-
cern economic costs to the legitimate market 
economy. There may therefore be significant eco-
nomic costs in drug-producing countries arising 
from substance misuse that are not measured in 
the COl framework. For example, the costs of cor-
ruption are not generally included in COl studies. 
Nor do COl studies generally attempt to measure 
costs arising from the economic disruption to legit-
imate business enterprises caused by large-scale 
illicit drug production and distribution. To do so 
would require a more extensive and demanding 
economic framework such as general equilibrium 
modelling. 
Estimates of the aggregate costs of substance 
abuse tend to attract a great deal of political and 
public attention. However, while the meaning of 
individual components of the aggregate costs (for 
example, the costs of health care or crime) is rela-
tively straightforward, the interpretation of the 
aggregate estimates requires great care and preci-
sion. To understand this point we need to return 
to the distinction between the human capital and 
demographic approaches to estimation. 
Both approaches relate to the valuation of the loss 
of production arising from the abuse-related 
deaths of otherwise productive members of soci-
ety. Both approaches compare production and 
abuse costs in the actual situation with those in a 
hypothetical alternative situation which would 
have existed had there been no past or present 
substance abuse. The difference between the two 
approaches relates to the way in which the pro-
duction costs of premature mortality are treated. 
The essential difference between the two 
approaches is summarized earlier in the following 
way. The human capital approach calculates the 
present and future production costs of abuse-
induced deaths which occur in the present year. 
The demographic approach calculates the present 
production costs of abuse-induced deaths which 
have occurred in past and present years. 
When looking at the human capital approach we 
are estimating the present value of the future time 
stream of lost productivity resulting from abuse-
induced deaths. Although we talk of the "costs of 
abuse in year X", in reality a high proportion of 
these production costs will be borne in years sub-
sequent to year X. In relation to the demographic 
approach, we are looking at the costs actually 
borne in year X but resulting from deaths not only 
in year X but also in many years prior to year X. 
Thus, interpretation of aggregate estimates is diffi-
cult, but unfortunately there is no way round this 
problem. If we calculated the costs borne only 
in year X as a result of deaths only in year X, the 
resulting costs would be very substantial underes-
timates of the overall costs borne by society since 
we would not account for the fact that deaths can 
impose costs over many years, not just in the 
years in which they occur. 
One implication of the way in which abuse costs 
are estimated is that the aggregate figures are not 
likely to change significantly over short periods of 
time. This is because rates of abuse and disease 
prevalence, the primary determinants of abuse 
costs, tend to change slowly. Thus it may well be a 
waste of research resources to undertake these 
estimates at intervals of less than three to five 
years. 
Some theoretical 
issues in the 
application of the 
framework 
The definition of drug abuse is rarely attempted in 
the literature, and those definitions that are avail-
able are not usually expressed in economic terms. 
For example, the definition used by the Mayo 
Foundation for Education and Research defines 
abuse as "consumption of any drug for purposes 
other than that for what it was intended or in any 
manner or in quantities other than directed". It is 
certainly difficult to apply this definition of abuse 
to the consumption of tobacco. 
A definition of abuse meaningful in epidemiologi-
cal terms is that "drug abuse is deemed to occur 
when a relevant aetiologic fraction is greater than 
zero, i.e. when drug abuse adversely affects the 
health of the user". A more comprehensive eco-
nomic definition, which encompasses non-medical 
costs such as accidents and policing, is that drug 
abuse exists when drug use involves a net social 
cost additional to the resource costs of the provi-
sion of that drug. Abuse occurs if the community 
incurs net costs as a result of drug use. 
The measurement of abuse may require different 
measures for different drugs. The measurement of 
abuse is most straightforward for tobacco. While 
most tobacco consumption must be considered 
addictive, all tobacco consumption can be consid-
ered abusive since all tobacco consumption dimin-
ishes health status. Abusive drug consumption 
may be, but is not necessarily, addictive consump-
tion. As an illustration, a road accident may be 
caused by abusive but not addictive consumption 
of alcohol. Harm minimization strategies for alco-
hol predominantly focus on the measurable effects 
of abuse such as health care costs and diminished 
health status, road accidents, and the costs of pre-
mature mortality. 
These and related data can be quantified so that 
economists can cost the amount of abuse which 
can be attributed to substance use, but they do 
not provide definitive measures on the nature and 
measurement of abuse. For example, a recom-
mended daily amount of alcohol consumption 
may be valid on a population-wide basis, but an 
individual may reach a level of abusive consump-
tion well before or well after the recommended 
consumption level. 
Indeed, an important issue in estimating the costs 
of alcohol is whether the counterfactual scenario is 
more appropriately no vs. low alcohol consump-
tion. Different studies have adopted different 
strategies. The choice of low consumption vs. 
abstinence as the counterfactual can have a signif-
icant bearing on the relative risk of morbidity and 
mortality associated with higher levels of alcohol 
use. The use of abstinence as a reference category 
for relative risks is less complicated, but it may 
decrease the estimated relative risks of high alco-
hol consumption for those disorders with a "J" 
shaped curve (having lowest risk among low level 
consumers compared to abstainers and heavier 
drinkers). The use of low consumption as a refer-
ence category for relative risks results in higher 
estimated risks of high alcohol consumption for 
disorders with a "J" shaped curve, but it ignores 
significant risks associated with low level con-
sumption for other disorders (e.g. traffic acci-
dents). 
When endeavouring to measure the abuse of illicit 
drugs, even less is known. Firstly, illicit drugs are 
not a homogenous category. In addition, the con-
venient definition that abusive consumption is 
equivalent to illegal consumption does not provide 
either an accurate basis for costing or a useful pol-
icy tool. However, while it may be much more 
useful to separate those costs which are incurred 
because of the legal status of a drug, e.g. law 
enforcement, not enough is known about abusive 
consumption of illicit drugs to produce a compre-
hensive measure of all other costs. 
The economist's definition of cost is based on the 
concept of an alternative use for scarce resources, 
known as opportunity cost. The measure of 
opportunity cost is the benefit which would be 
derived from the best alternative use of a particu-
lar resource. For example, the alternative use of 
land which is currently used for growing tobacco is 
the next most valuable crop which could be pro-
duced on that land. 
A number of issues relate to costs, for which 
understanding of definitions is important. It is gen-
erally recognized that the costs of abuse include 
private costs and social costs, about which 
Markandya and Pearce (1989) say: "to the extent 
that the costs are knowingly and freely borne, 
they are referred to as private costs, but to the 
extent that they are not so borne but fall on the 
rest of society they are referred to as social costs". 
In estimating the costs of drug abuse, other types 
of costs which require definition include tangibles 
and intangibles. Tangible costs can be defined as 
those costs which, when reduced, yield resources 
which are then available to the community for 
consumption or investment purposes. Intangible 
costs, which include pain and suffering, when 
reduced or eliminated do not yield resources avail-
able for other uses. As much of the efforts of the 
health care system are focused on the reduction of 
intangible costs, it is apparent that these costs are 
very important, albeit difficult to quantify. 
It is also important to identify the concept of mar-
ginal cost, which is the increase in total cost attrib-
utable to drug abuse after allowing for the costs 
which would have otherwise been incurred in the 
absence of any drug abuse. In other words, this is 
a net cost concept. 
For example, in costing health care, net costs 
include estimates of both incurred health care 
costs and potential savings. Those health care 
costs which are attributable to substance abuse 
should be set against the saving in health care 
costs which have resulted from the premature 
deaths of drug abusers. Had the abusers not died 
from causes related to drug abuse they would in 
many cases still be alive, suffering from other dis-
eases and so imposing health care costs on the 
community. If abusers were not sick from abuse-
related causes they would, in many cases, be sick 
from other causes. 
It should also be noted that the resulting cost fig-
ures in COl studies are generally the aggregates of 
the individual costs which fall upon individuals 
directly or through agencies they have an interest 
in (such as the government). It is an assumption-
a convention, rather than a scientific principle-
that the sum of these individual costs are equal to 
the aggregate social cost. Any alternative conven-
tion is likely to involve more complex assumptions. 
The user of any social cost aggregate (indeed of 
just about any economic aggregate) needs to be 
aware of this assumption, and where necessary to 
go below it to a deeper level if the particular issue 
requires. The suggestion of disaggregating the 
total into institutional sectors (in Section 4) alerts 
the user to the aggregation issue and enables 
some insights. 
Difficulties arise in practice in estimating the pro-
portion of consumption which is addictive, 
although reasonable estimates can be made. There 
are strong grounds for the belief that drug use by 
addicts does not yield private benefits. 
The theory of rational addiction, proposed by 
Becker and Murphy (1988), implies that persons 
contemplating the possibility of acquiring an 
addiction maximize their utility over time in the 
knowledge of the interdependence of present con-
sumption and future preferences and with full 
knowledge of the effects of the contemplated 
addiction. In other words, the theory requires that 
potential addicts have full knowledge of all the 
drug's present and future effects at the time at 
which they are deciding whether to acquire the 
addiction. It is, considering the medical literature 
on the nature and sources of addiction, extremely 
difficult to believe that addicts make rational con-
sumption decisions. It is even harder to believe 
that potential addicts have access to, and the abili-
ty to evaluate, all the relevant medical and epi-
demiological information in advance of becoming 
addicted, particularly when so many addicts are 
young or became addicted when they were 
young. 
Ellemann-Jensen (1991) points out that total 
addiction has been assumed to imply that the 
smoker enjoys no utility at all from smoking but 
continues to smoke. He suggests that "such 
behaviour is clearly in contrast to the hypothesis of 
utility-maximization in standard economic theory". 
But, in fact, this is not necessarily the case. A 1991 
editorial in the British Journal of Addiction sug-
gests that addiction involves, inter alia: 
,. highly compulsive use; 
use despite harmful effects; 
relapse following abstinence; and 
recurrent drug cravings. 
In this circumstance, the objective of drug con-
sumption may well be to avoid highly unpleasant 
effects of withdrawal rather than to gain any posi-
tive benefits. Since the withdrawal effects result 
from previous consumption of the addictive drug, 
avoidance of these effects can hardly be viewed as 
a benefit of drug consumption. Short-run utility 
maximization need not necessarily imply long-term 
positive overall benefits from drug use. 
The proportion of total consumption of an individ-
ual drug which is addictive consumption varies 
from drug to drug. For example, approximately 
90% of Australian tobacco consumption has been 
estimated to be addictive but it is to be expected 
that the proportion of alcohol consumption which 
is addictive is considerably lower. The proportions 
applying to the various illicit drugs will also vary 
substantially. 
Two broad approaches have been adopted to the 
estimation of the costs of substance use- the 
widely adopted "human capital" approach and 
the more recent "demographic" approach. Both 
approaches relate to the valuation of the loss of 
production arising from the abuse-related deaths 
of otherwise productive members of society. Both 
approaches compare production and abuse costs 
in the actual situation with those in a hypothetical 
alternative situation which would have existed had 
there been no past or present substance abuse. 
The difference between the two approaches 
relates to the way in which the production costs of 
premature mortality are treated. 
The human capital approach is to estimate the 
value of the worker's future production stream, 
brought back to present day values by the use of 
an appropriate discount rate. A thousand dollars 
received this year is worth more than a thousand 
dollars received next year (even if there is no infla-
tion) because this year's resources become avail-
able for investment purposes a year earlier and so 
produce interest receipts or profits a year earlier. 
The use of a discount rate acknowledges this fact 
and adjusts for the difference between present 
and future values. Two major problems arise in the 
human capital approach- how to forecast future 
production levels and how to choose the appropri-
ate discount rate. 
The demographic approach compares the actual 
population size and structure with the size and 
structure of the hypothetical alternative no-abuse-
population. From this comparison the actual and 
hypothetical outputs are compared to yield the 
production costs in that year of past and present 
substance abuse. The major problem in this 
approach is the estimation of the alternative popu-
lation structure. 
The essential difference between the two 
approaches can be summarized in the following 
way. The human capital approach calculates the 
present and future production costs of abuse-
induced deaths that occur in the present year. The 
demographic approach calculates the present pro-
duction costs of abuse-induced deaths that have 
occurred in past and present years. Which 
approach should be adopted depends, therefore, 
upon which type of information is needed. The 
two approaches are complementary rather than 
competitive. 
The estimation of economic costs associated with 
substance abuse applies to a particular period, typ-
ically a recent year. However, the effect of the 
counterfactual scenario may involve cost savings in 
later years. The standard economic procedure is to 
"discount" such costs in the future to an equiva-
lent sum in the base period. The base period 
amount is smaller than the actual amount, even 
after adjusting for inflation, because events in the 
future are not given much (economic) value in the 
present. 
The actual discounted amount can be very sensi-
tive to the discount rate chosen. There is no inter-
nationally agreed upon discount rate, and even in 
a single country economists dispute the appropri-
ate rate. These guidelines do not attempt to 
resolve this issue. Instead, it is proposed that 
where discount rates are required for the purpose 
of estimating the costs of substance abuse, the 
study should provide several estimates corre-
sponding to different discount rates. While the 
preferred discount rate will vary between coun-
tries, it is further suggested that cost estimation 
studies include discount rates of 5 per cent and 10 
per cent among those provided in order to facili-
tate comparability to studies in other countries. 
The overall costs to the community of substance 
use can be subdivided into private costs and social 
costs. If the costs of substance production and use 
are knowingly and freely borne by producer or 
consumer as the result of a rational decision-mak-
ing process they should be classified as private 
costs. It can be assumed that, in these circum-
stances, there exist private benefits of production 
or consumption which at least equal the private 
costs. 
There are three circumstances under which the 
consumer will not have rationally, knowingly and 
freely borne the full costs of the substance use: 
there may not be available full information as to 
the costs which substance use imposes on the 
user; 
the consumer may not make a rational decision 
based upon the costs of substance use which 
must be borne by the user; 
there may be no mechanism by which the costs 
which substance use imposes on the rest of the 
community (the external costs) can be converted 
into internal costs to be directly borne by the 
user. For example, it might not be possible for 
smokers to be forced to bear their full health 
costs or to provide recompense for the costs 
which they impose upon passive smokers. 
Thus, if the costs of substance use are to be classi-
fied as private costs, the following three conditions 
must be simultaneously satisfied: 
1. The users are fully informed as to the costs 
which the substance use imposes upon them-
selves; 
2. The users are required to bear the full (internal 
and external) costs of the consumption; and 
3. The users make rational consumption decisions 
in the light of all the information available to 
them. 
These requirements are extremely stringent, so 
stringent in fact that the conventional approach of 
treating all abuse costs as social costs is fully justi-
fied. 
The major intangible costs of substance use to be 
considered here are caused by death, pain, suffer-
ing and bereavement. The most important charac-
teristic of intangible costs is that, when they are 
reduced, there is no release of production or con-
sumption resources for other uses. For example, 
any reduction of pain and suffering, while an 
important benefit, will permit no direct transfer of 
these benefits to any other person. An important 
implication of this characteristic is that there is no 
market in the benefits of cost reduction -the ben-
efits cannot be bought and sold. Thus it is 
extremely difficult to place a value upon intangible 
costs and the temptation exists to ignore them. 
However, to do so may lead to misleading and 
unreasonable results. 
To illustrate the potential problem involved in 
ignoring intangibles, take the case of the costs of 
smoking. A high proportion of smoking-induced 
deaths occur beyond the age of retirement, in 
which case the community receives a tangible 
benefit (forgone consumption exceeding forgone 
production). To ignore intangible costs could lead 
to the conclusion that smoking, by leading to the 
premature deaths of retirees, could benefit the 
community as a whole. The evidence that this 
conclusion is unreasonable is that most societies 
devote very considerable health resources to 
extending the lives, and reducing the pain and 
suffering, of people of beyond working age. They 
do not cease to be of value to society simply 
because they cease to work. 
The valuation of life is quite generally attempted 
in many advanced countries- for example in ben-
efit-cost analysis of road or rail investments. The 
two basic approaches to the valuation of life are 
the "human capital" and "willingness to pay" 
techniques. 
The human capital approach estimates the dis-
counted current value of the future stream of 
potential earnings of the victim. This approach 
undervalues life since it takes no account of the 
value of life to the victims over and above their 
earnings loss. To avoid death or sickness, most 
substance users would be willing to pay much 
more than simply their lost future earnings. The 
human capital approach can take account of this 
objection by arbitrary scaling-up of the estimated 
values but the theoretical basis for choice of the 
scaling factor is exceedingly weak. Nor does it 
simply include that many people make contribu-
tions to welfare even though they are not paid for 
it (as discussed later in Section 4.4.3). There can 
be a scaling up or imputation, but again the theo-
retical underpinning is weak. 
The willingness to pay approach studies what peo-
ple would be willing to pay for relatively small 
changes in the risk of death and from these fig-
ures produces estimates of the value of life. While 
this technique appears to have a much sounder 
theoretical basis, there still remain considerable 
difficulties in the accuracy and consistency of esti-
mates using this approach. 
Furthermore, when cost studies utilize a willing-
ness to pay method for valuing life, it is no longer 
appropriate to compare the total costs of sub-
stance abuse to the Gross Domestic Product, as 
the total value of life using willingness to pay 
techniques is generally much higher than the GDP. 
One resolution to this problem is to compare the 
value of life in the cost of illness study to the total 
value of life in a society. This is elaborated in 
Appendix C. 
There is no internationally agreed method of evalu-
ating the value of human life. Some of the method-
ological differences include: 
some are based primarily on the loss of market 
productivity (which may be augmented by loss of 
non-market productivity); 
some impute a separate value of life above that of 
any loss of production, to reflect a human loss of 
death, pain and suffering. Common methods for 
doing so include measuring the number of deaths, 
or the decrease in the quality adjusted life years 
(QALYs) or the decrease disability adjusted life 
years (DALYs), valued by some monetary unit 
which may (or may not) be derived from willing-
ness-to-pay studies. The use of QALYs and DALYs 
instead of deaths means that the assessment 
includes a valuation for deterioration in the quality 
of life while alive, while the number of years of life 
lost as a result of a death are given some weight. 
Thus, using QALYs and DALYs in preference to the 
number of deaths gives relatively higher social 
costs of abuse that is more likely to result in death 
at a relatively early age (e.g., from alcohol or illicit 
drug misuse) than where deaths occur at a later 
age (e.g., from tobacco use). 
Different countries (and different economists) adopt 
different methods because, among other things their 
method: 
may be institutionalized by some official require-
ment; 
may be the conventional practice of the local pro-
fession; 
there may not be the data for the alternative 
method, or disagreement about key parameters; 
key data may be subject to an unsatisfactorily 
large margin of error. 
This section is about where the value of human 
life includes an element in addition to that from 
the loss of production. It assumed that either the 
loss of material production (the tangible costs) has 
been treated separately in another calculation or 
separated out and that element is included in the 
material costs. However, for reasons described 
elsewhere it may still be appropriate to include an 
"intangible" component. The concern here is that 
if life is based on a willingness-to-pay method, for 
example, then the value of lost life numerically 
overwhelms the cost of material production. For 
instance, an estimate might find that the material 
costs (including loss of potential productivity) from 
substance abuse might amount to, say, 3 percent 
of GDP, but a value of life based on willingness to 
pay amount to ten times this figure. 
The above point warrants further explanation. 
Gross Domestic Product (GDP) is the national 
accounting measure of production occurring in a 
whole economy during an accounting period (usu-
ally a year). It represents the value of goods and 
services produced in the domestic economy in that 
period. It does not include certain items routinely 
incorporated in estimates of the social costs of 
substance use. These include mainly intangibles 
such as the value of loss of life pain and suffering 
but also tangibles such as the value of unpaid 
work. To compare estimates of the social costs of 
drug abuse with GDP can be a misleading exercise 
since like is not being compared with like. Social 
cost estimates incorporating the value of loss of 
life can appear to be very high in relation to GDP 
because the value of life is not a part of GDP. It is 
an intangible, not a tangible and it is, in the eco-
nomics jargon, a stock not a flow. It is, however, 
certainly possible to compare GDP with those 
components of the social cost estimates which are 
included in GDP estimates. This point is developed 
in Appendix C. 
It is often argued (for example, by the tobacco 
industry) that if the industry producing the abused 
substance ceased to exist there would be a sub-
stantial social cost in terms of the resulting losses 
of output, income and employment. Thus the out-
put, income and employment generated by the 
industry are represented as being benefits that the 
community receives from the production of the 
abused substance. However, this analysis rests 
upon two important assumptions, both of which 
are open to very serious question. 
The first assumption is that, in the absence of any 
spending on the abused substances, the money 
would not have been used for any other form of 
expenditure- it would simply have been saved. 
This is highly unlikely. Most probably the money 
would have been spent on other forms of con-
sumption that would have yielded very similar lev-
els of output, employment and income. 
The second assumption is that the resources used 
in drug production would have had no alternative 
uses. For example, the farmland used to grow 
tobacco would have been unsuitable for the culti-
vation of any other crop, and the farm labour 
employed in tobacco growing or in the manufac-
ture of cigarettes would be qualified for no other 
type of employment at all. This assumption is also 
highly implausible. 
The question does arise, however, as to whether 
employment would have been available for these 
people, in a situation in which there was substan-
tial unemployment. If, however, as a result of the 
decline of the tobacco industry, only the pattern of 
consumption in the economy changes, rather than 
there being any decline in total consumption, any 
job losses in the industry will be broadly matched 
by job gains elsewhere in the economy. From a 
societal viewpoint, there is likely to be little change 
in levels of employment and unemployment. 
An issue related to this is the question of whether 
abuse-related mortality causes any production loss 
during periods of significant unemployment since, 
it is often asserted, the dead can be replaced from 
the ranks of the unemployed who were not previ-
ously productive. Thus, the argument goes, in 
periods of high unemployment the production 
losses from abuse-related mortality are low or 
zero. Again it is necessary to examine the assump-
tions underlying this analysis. 
It assumes that the skills of the dead workers can 
also be found in the ranks of the unemployed. 
However, one of the major characteristics of the 
unemployed is that they tend not have the skills 
demanded by employers. They are, in economic 
jargon, structurally unemployed. In many cases, 
therefore, the dead are not replaceable. The analy-
sis also assumes that the unemployed are making 
no contribution to society in any unpaid capacity. 
Again, this is not a plausible assumption. 
A difficulty with the assumption that abuse-related 
mortality causes no production loss in periods of 
high unemployment is that the calculated social 
costs of substance abuse fall as the unemployment 
rate rises. This means that the human capital 
approach necessitates the forecasting of future 
unemployment rates. This is a notoriously unreli-
able process since unemployment levels are par-
tially determined by factors beyond the control of 
national governments, for example, changes in oil 
prices or in technology. In practice, cost estimates 
of abuse-related production losses are almost 
always made on the implicit or explicit assumption 
that the dead are irreplaceable. 
It is assumed that the hypothetical alternative situ-
ation in which there is no drug abuse is simply 
that: hypothetical and not realizable under any cir-
cumstances. Estimates of the total costs of drug 
abuse comprise both avoidable and unavoidable 
costs. Unavoidable costs comprise the costs which 
are currently borne relating to drug abuse in the 
past, together with the costs incurred by the pro-
portion of the population whose level of drug con-
sumption will continue to involve costs. Avoidable 
costs are those costs which are amenable to public 
policy initiatives and behaviour changes. 
An estimate of the percentages of mortality and 
morbidity that are avoidable was made in a com-
parative study by Armstrong in 1990. Armstrong 
(1990) uses an "Arcadian normal", which is the 
lowest age-standardized mortality rate for the rel-
evant mortality or morbidity category amongst 
twenty selected, comparable Western countries. 
He implies that the Arcadian normal is the lowest 
percentage of preventable morbidity and mortality 
yet achieved in any of the chosen countries. This 
could suggest that no further improvement is pos-
sible. This appears to be an extremely conservative 
assumption, but nevertheless is a very useful tool 
for quantification of the percentage of preventable 
morbidity and mortality and their associated costs 
which can be reduced, and ultimately avoided. 
Some of the identified costs of abuse, while avoid-
able, may be reduced or eliminated only over long 
lead times, which can be considered in three cate-
gories. Firstly, policy implementation lead times 
will not be effective instantaneously. Secondly, 
even after full and effective implementation of 
policies, there will be long lead times before the 
heath effects of policy changes are achieved. For 
example, the significant health gains from ceasing 
to smoke take between five and fifteen years to 
work their way fully through. Thirdly, as some 
costs apply to premature mortality, it will be years 
before the population structure reflects the avoid-
able reduction in abuse, and the associated avoid-
able costs. 
A basic distinction between cost estimation studies 
is whether they are incidence-based or prevalence-
based. In epidemiology, the term incidence gener-
ally refers to the number of new cases of a given 
disease or disorder that occurs in a given period of 
year (typically one calendar year) in the general 
population. An incidence-based cost estimation 
study uses an estimate of the number of new cases 
to estimate the economic costs in that one year 
and into future years. The essence of an incidence-
based approach is the determination of a per-case 
lifetime cost estimate that can be applied to new 
cases. Incidence-based costs are quite important in 
performing cost benefit analysis (CBA) or cost 
effectiveness analysis (CEA). They portray and sum 
the magnitude of the economic impacts in each 
year of the individual's expected life from the date 
of onset of substance abuse. Thus, they provide us 
with critical insight into the value of preventing a 
case of substance abuse. This can be contrasted to 
the cost of preventing that case (whether through 
demand reduction or supply reduction). Incidence-
based cost estimates may also be useful in the 
study of treatment, where the analysis begins at 
the age and date where treatment is initiated, and 
continues across their expected life. Incidence-
based approaches have been used to estimate the 
costs of HIV infection and tobacco. 
Many Cost-of-Illness studies, however, use a 
prevalence-based approach. In epidemiology, the 
term prevalence generally refers to the number of 
cases of a particular disease or disorder occurring 
in the general population at a given point in time. 
Rather than considering the life cycle of substance 
abuse as in an incidence-based approach, preva-
lence-based studies estimate the number of cases 
occurring at a given time to estimate the economic 
costs in a given year. Prevalence-based estimates 
therefore include for a given year not only the 
immediate costs of new substance abusers (newly 
incident), but also the costs of mature substance 
abusers and even of former substance abusers that 
still have problems (e.g., HIV, liver cirrhosis or res-
piratory illness) after they have stopped use of 
drugs, alcohol and tobacco, respectively. 
Both incidence and prevalence-based approaches 
are useful for addressing somewhat different 
research questions. For example, in AIDS research 
both incidence-based and prevalence-based esti-
mates have been used to address different policy 
issues. Incidence-based studies estimate the costs 
associated with new cases in the current year and 
into the future, while prevalence-based studies 
estimate the costs associated with past and current 
use in the current year. It should be noted, howev-
er, that those prevalence-based studies that use a 
human capital approach to estimate indirect pro-
ductivity costs do consider some future costs in 
that these studies include estimates of the fore-
gone productivity of those who die prematurely 
from substance abuse. 
Certain types of crime involve no apparent "vic-
tim" and are sometimes termed "consensual" or 
"victimless" crimes. These are activities such as 
sex for pay, illegal gambling and the illegal drug 
trade. In some nations it is not uncommon to find 
some drug dependent persons in these profes-
sions. Consequently, in COl studies of substance 
abuse, consensual crime can make up part of the 
cost of crime. Economic resources used to enforce 
laws against drug possession and distribution are 
typically included in COl studies of the costs of 
illicit drugs. Similarly, some cost studies include an 
estimated cost for "criminal careers", based on the 
estimated value of foregone production by per-
sons employed in illicit production or trade in 
abused substances. 
In addition to these costs for consensual crime, the 
costs of some other crimes may be reasonably 
included in COl studies. There is little doubt that 
there is a strong statistical relationship between 
drug use and non-consensual crime. Criminal 
offenders have disproportionately high rates of 
illicit drug use. In Canada, for example, up to 80% 
of offenders report using illicit drugs during their 
lifetime, 50-75% show traces of drugs in their 
urine at the time of arrest, and close to 30% were 
under the influence of drugs when they commit-
ted the crime for which they were accused 
(Brochu, 1995). By the same token, drug users in 
treatment often have criminal records (see, e.g., 
Hallet al., 1993; Elnitsky & Abernathy, 1993). For 
example, more than four-fifths (81 %) of Toronto 
injection drug users have been incarcerated since 
they began using intravenously (Millson et al., 
1995). 
However, the fact that a crime is committed by 
someone using illicit drugs doesn't necessary mean 
that the drug use caused the crime to be commit-
ted. There is clearly a relationship between illicit 
drug use and crime, but it is not always causal. 
There are several plausible causal connections 
between drugs and crime: 
The pharmacological effects of drugs: The con-
sumption of certain illicit drugs might induce 
violent behaviour. Although many illicit drugs are 
negatively related to violence (e.g., cannabis and 
heroin tend to reduce aggressive behaviour), 
cocaine, other stimulants and PCP could produce 
violence by the loss of ego control, deterioration 
of judgment, induction of irritability and impul-
siveness or the production of paranoid thoughts. 
However, the mechanisms for this relationship 
are in doubt and generally it appears that vio-
lence stemming from the pharmacological 
effects of illicit drugs is uncommon and cannot 
be attributed only to drug use (Abram and 
Teplin, 1990). Many, indeed most, drug depen-
dent persons who commit violent crimes began 
doing so prior to becoming drug dependent 
(Kreuzer, 1993). This would indicate that the 
pharmacological effects of the drugs are at best 
only a partial explanation for their violent 
behaviour. 
The need for drug users to commit crime to sup-
port their drug use: Some people dependnet on 
heroin and cocaine are involved in crime to sup-
port their drug habits. For example, some sex 
trade workers may be involved in prostitution to 
support a drug habit and some dependent users 
commit property crime to support their drug use. 
These crimes are presumably committed because 
the addict's physical need for drugs is so strong 
that the demand for drugs is inelastic- no mat-
ter what the price, the user must obtain his or 
her drugs. However, the presumption that drug 
use invariably leads to crimes of acquisition is 
challenged by a number of observations. First, 
the majority of illicit drug users are not depen-
dent. Second, most users, even dependent users, 
do not commit property crimes. Third, those 
dependent users who do commit property 
crimes tend to use drugs at very high levels, 
they have few legitimate sources of income and 
in the majority of cases they were engaging in 
criminal behaviour prior to drug use (Brochu, 
1995). Third, the demand for illicit drugs is more 
responsive to price than is commonly believed: 
"An addict can use 2 grams on one day and 
nothing on the next. It is not the physical need 
that determines the amount of money needed, 
but the money available that determines the 
quantity of drugs consumed" (Grapendaal, 
1992). Further, many former drug dependent 
persons continue to commit property crimes 
even when they no longer use drugs 
(Hammersley et al., 1989). As with the pharma-
cological explanation, this connection between 
drugs and crime undoubtedly plays a role in 
many cases, but it is only a partial explanationY 
Crime results from systemic violence inherent in 
the illicit drug trade: There is little doubt that 
some crimes result from "turf wars" between 
rival distributors as well as arguments and rob-
beries involving buyers and sellers on the illicit 
market (Roth, 1994). Systemic violence in the 
illicit drug market is most common in economi-
cally and socially disadvantaged areas that have 
traditionally high rates of violence. It should also 
be noted that drug dependent persons are not 
only more likely to commit crimes, they are also 
more likely to be victims of violent crimes and 
they have a high victim tolerance: "They do not 
renounce one another for fear, habit and self-
protection" (Kreuzer, 1993: 78). 
There is yet another connection that may account 
for most of the relationship between drug use and 
crime, but it is not a causal link. Many drug 
dependent persons adopt a way of life that 
accounts for both their drug use and their criminal 
behaviour. A number of longitudinal studies have 
shown that drug use and criminality are related to 
a similar set of socio-demographic and personality 
variables- e.g., poverty, poor future career or 
income prospects, and a low investment in social 
values (Brunelle and Brochu, 1995; Fagan et al., 
1990; McBride and McCoy, 1981 ). There are 
undoubtedly many common underlying causes of 
both criminality and illicit drug use. Drug use and 
crime may well be mutually reinforcing, but 
according to this viewpoint, the real cause of both 
drug use and criminal behaviour are a complex set 
of underlying personality and social determinants. 
There is thus little doubt that drugs are a con-
tributing causal factor in some crimes, but the fact 
that a crime is committed by a drug user, even 
when he or she is under the influence of drugs, 
does not necessarily mean that the crime can be 
ascribed to drug use. The pharmacological effects 
of the drugs themselves account for few crimes, 
and a substantial proportion of crimes attributable 
to drugs stem from the fact that users must obtain 
their drugs from a violent and high priced illicit 
market. Much of the relationship between drug 
use and crime stems from the fact that some drug 
users have a lifestyle involving both drug use and 
criminality, and it is not at all certain that the crim-
inality would not occur without the drug use. Like 
other "consequences" (e.g., violent crime, motor 
vehicle crashes, HIV infection) that may be partial-
ly attributed to substance abuse along with other 
factors, only some fraction of crime should be 
included in the costs. An attributable risk factor 
needs to be developed. 
The 1994 First International Symposium on 
Estimating the Social and Economic Costs of 
Substance Abuse concluded that it would be desir-
able to indicate which community groups were 
bearing the social costs of substance abuse. A 
major reason for this recommendation was recogni-
tion of the fact that the incidence of these costs 
may change, even in situations in which the overall 
costs are stationary. For example, there is a signifi-
cant international trend in the financing of health 
care to encourage a greater proportion of funding 
of health care by private individuals rather than by 
the state. Aggregate abuse cost estimates will not 
reveal this type of effect, whereas incidence esti-
mates will. 
Abuse costs can be treated as a form of tax and 
analyzed in a similar way. The costs can initially 
bear on one or more of four broad domestic com-
munity groups- the abusers themselves, other indi-
viduals, the business community and government-
or they could be exported. As examples of these 
types of incidence of smoking costs we may cite 
the following: 
Abusers - the physical and psychological pain of 
death from smoking-related cancers; 
Other individuals- detrimental effects of environ-
mental tobacco smoke (passive smoking) and 
some intangible costs (all intangible costs will, by 
their nature, be borne by individuals, either 
abusers or others; sometimes it may make sense 
to separate out the impacts on family and near 
relatives from the public at large); 
Business- production losses resulting from smok-
ing-related mortality, absenteeism and reduction 
in on-the-job productivity; 
Government- funding of smoking-related health 
care. 
Exported- drug-related increases in production 
costs could be shifted to foreigners in the form 
of higher prices for exported goods and services. 
It is possible that these broad groups may be in a 
position to pass on the costs to some other group. 
For example, business may be able to pass on the 
costs of productivity losses to consumers in the 
form of higher product prices or to workers in the 
form of lower wages. This type of analysis is, 
however, fraught with problems since it is difficult 
(if not impossible) to know how costs are "shift-
ed" in practice. Furthermore, all costs initially 
borne by business or government must eventually 
be borne by individuals (as consumers, workers, 
shareholders or taxpayers) either at home or 
abroad. Thus, incidence analysis should be con-
fined to examining the initial burden of abuse 
costs among the community groups enumerated 
above. 
It is important to appreciate that the social costs of 
substance abuse are not borne solely by the public 
purse. First, some costs may be incurred outside of 
the national economy. For example, there are sub-
stantial drug interdiction programmes funded by 
the U.S. government in South American and other 
Third World countries. While the costs for foreign 
programmes are included in U.S. cost estimates, it 
would be dubious to include costs paid by foreign 
governments in estimates of the costs of drugs for 
those countries in which the programming occurs. 
In a sense, these enforcement costs have been 
exported. More importantly, even when economic 
costs are borne domestically, a significant propor-
tion of these costs may well be borne by individu-
als (for example, by the families or victims of drug 
addicts or by non-smokers exposed to environ-
mental tobacco smoke). Again, in many circum-
stances, employers may bear these costs rather 
than government or the abusers themselves. Thus 
it should be appreciated that the following discus-
sion on the budgetary impact of substance abuse 
relates to the impact of only probably a small pro-
portion of total social costs. 
In addition to the call which substance use places 
on real resources, it puts pressure on government 
budgets as a result of the need to fund such drug-
attributable expenditures as health, welfare, drug 
prevention and the enforcement of drug laws. 
However, the use of substances such as alcohol 
and tobacco also produces government revenue, 
mainly as a result of the high consumption and 
excise taxes that these products bear in many 
countries. Calculation of the impact of substance 
abuse on government budgets, therefore, involves 
estimating both expenditures and revenues result-
ing directly or indirectly from substance use. 
On the outlay side of the drug budget there will 
clearly be increased expenditures attributable to 
substance use but there will also be some drug-
attributable reductions. In particular, premature 
mortality resulting from drug use will lead to some 
reduction in welfare and health expenditures. Net 
health and welfare expenditures attributable to 
substance use will almost certainly be positive 
even after these "savings" are taken into account. 
On the revenue side, in addition to the evident 
gains there will also be losses in revenue. 
Premature mortality will lead to reduced output, 
incomes and consumption and so to reductions in 
revenue from personal income tax, company 
income tax and indirect taxes. The major compo-
nents of a study of the budgetary impact of smok-
ing are presented below in Figure 1. 
Extreme care should be taken in interpreting such 
estimates of budgetary impact. The results of 
these calculations certainly do not indicate 
whether drug users cover all the costs that they 
impose on the rest of the community. This is 
FIGURE 1 -A DRUG ABUSE BUDGET 
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Reduced welfare payments to abusers 
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Health 
because some of these "external costs" do not 
show up as government expenditures (for exam-
ple, the loss of production resulting from the 
health effects of passive smoking). 
It could not be argued, for example, that "smok-
ers pay their way" simply on the basis that tobac-
co-related tax revenues exceed tobacco-related 
public expenditures. Nor could it be argued that, 
even if the net impact of smoking on government 
budgets were shown to be positive (that is, smok-
ing reduced the budget deficit or increased the 
budget surplus) then smoking was in the public 
interest. Budgetary estimates totally ignore, inter 
alia, the costs of loss of life, pain and suffering 
caused by drug use 
A further type of calculation is the so-called "drug 
budget" which is a public policy indicator measur-
ing the expenditure effort made by the state in the 
fight against drugs by adding the entire budgeted 
expenses attributable to drugs policies. Public deci-
sion makers in the drugs policy area almost univer-
sally have limited resources at their disposal. 
Measurement of government expenditures on the 
fight against drugs, the "drug budget", represents 
one of the main statistical indicators that can be 
made available to public policy makers. The drug 
budget should not be confused with the "social 
costs of drug use" which is an estimate indicating 
the resources which have become unavailable to 
the community because of drug use, and which 
could be used elsewhere if the drug problem was 
CHANGE IN RECEIPTS 
Increases 
Sales taxes 
Value added taxes 
Customs duties 
Excises 
Other consumption taxes 
Less decreases 
Personal income tax 
Company income 
Indirect taxes (less subsidies) 
~~~~~~~~·~~~~~~~~~~~~~~·~~~~~~~~~~~~~~~·~~~~· 
suppressed. In the countries for which results are 
already available, the drug budget on average rep-
resents only about 5% of the social costs of drugs 
use. Nor should drug budget estimates be con-
fused with the budgetary impact estimates pre-
sented in Figure 1. Drug budgets do not include 
social transfer payments. They only include direct 
government expenditures for policy costs such as 
treatment, enforcement, prevention and research. 
Government expenditure on drugs can be classi-
fied into two types. On the one hand, there are 
expenditures detailed in public finance statistics, 
such expenditures as anti-smoking education and 
smoking-related research, which are directly relat-
ed to drug problems. On the other hand, general 
authorities, such as the police, customs and public 
health institutions dedicate part of their resources 
to deal with problems generated by drugs, usually 
without specifically identifying the drug-attribut-
able component of their expenditures. In almost 
all cases these authorities would not, in fact, have 
sufficient information to make such attribution. 
The evaluation of drug-attributable expenditures 
of this type is rarely attempted, yet they are 
undoubtedly an important component of overall 
government expenditures resulting from substance 
abuse. 
In practice, such calculations are sometimes made 
in the field of the treatment of drug dependence. 
Administration of health costs reimbursement 
often results in the routine collection of cost data 
by diagnosis, which permits the development of 
cost estimates for health problems attributable to 
substance abuse. In contrast, the operation of 
policing and criminal justice often does not require 
separate accounting for activities resulting from 
substance misuse. Consequently, this type of infor-
mation is not available unless countries finance 
special studies to estimate the attributable portion 
of such services resulting from substance abuse. 
Not until the difficulties arising from the lack of 
statistical data have been overcome will it be pos-
sible to undertake international comparisons of 
drug budgets. For drug budgets to be compared, 
they should be expressed in terms of percentages 
of other standardized macro-economic aggregates. 
For example, the ratio of the drug budget to GDP 
or the ratio of the drug budget to overall public 
expenditure may be used as an indicator of the 
commitment by the state to dealing with sub-
stance abuse. 
Comparison of overall drug budgets may also be 
complemented by an analysis of their composition. 
Drugs policy may be classified into two groups of 
expenditures: enforcement and treatment. 13 
Enforcement expenditure relates to, inter alia, the 
costs of the running of the police forces and of the 
judicial and jail systems. Treatment expenditure 
relates to the sums dedicated to the treatment of 
the consequences of the drug consumption. 
Examination of the balance of expenditures 
between enforcement and treatment by public 
authorities often shows that enforcement is the 
major component of the drug budget. This results 
not only from policy choices but also for statistical 
reasons. First, enforcement agencies (police, courts 
and corrections) are often more centralized than 
those giving medical care, thus making it easier to 
identify the expenditures for enforcement. In addi-
tion, court costs are often considerable and impris-
onment is expensive, particularly when prison con-
ditions are good by international standards. 
The guidelines described in this report are based 
on the assumption that the factors of production 
used in local drug production (land, labour, capital, 
etc.) can easily shift into other industries if there is 
a reduction in demand (or, if the substances are 
imported, the foreign exchange saved is used for 
supplying other imports). The underlying method-
ology is what economists call "partial equilibrium". 
However in some cases the counterfactual sce-
nario may involve a major adjustment to the econ-
omy (and society) because changes to the drug 
production sector of the local economy are suffi-
ciently large to impact on the whole economy. 
The assessment of the costs of substance abuse in 
countries with large-scale drug production would 
thus entails a more complex analysis using a "gen-
eral equilibrium" approach, which is a well-estab-
lished procedure for estimating the impact of-
among other things- industry closure. A general 
equilibrium analysis would provide an estimated 
value of GDP while the industry is functioning, 
and compare this to the estimated value of the 
GDP after the industry is closed down or reduced 
substantially in scale. The difference (after adjust-
ing for price changes) is loss of social welfare, or 
the social cost of closure or scale reduction. While 
utilizing much the same principles as those on 
which the guidelines are based, this would entail 
an extension beyond the scope of these guide-
lines. Additionally, where the industry was operat-
ing illegally it is extremely difficult to quantify the 
effects of any drug-related corruption on human 
welfare, as well as institutional instability created 
by illicit drug production and other adverse effects 
(such as environmental damage caused by control 
measures). Because of such factors, the guidelines 
do not cover those cases where there is a substan-
tial drug producing industry, although Appendix B 
elaborates some of the issues. 
The geographical unit for evaluating the costs of 
substance abuse is typically a nation. However, the 
guidelines can be used to evaluate a smaller geo-
graphical entity, such as a province, state or region 
in a federation. It may be that illicit drug produc-
tion in a smaller entity may have a significant 
impact on the local economy, in which case the 
remarks of the previous paragraph are relevant. 
Sometimes the geographical unit will be a group 
of nations. Again the guidelines should remain 
robust for that purpose. 
Towards a common 
framework: 
the matrix of costs 
and issues of 
measurement 
Perhaps the first issue in designing a framework of 
what to include in estimating the economic costs 
of substance abuse is the issue of which psychoac-
tive substances should be covered in the study. 
There is probably no right or wrong answer in 
making this determination. 
Studies may reasonably focus on a single sub-
stance or on many substances. However, the 
determination of scope has definite implications in 
terms of the level of effort, the data requirements, 
and the analytic requirements. In practice, analysts 
have generally performed studies of the cost of 
abuse of and dependence on: 
" alcoholic beverages; 
tobacco products; 
illicit drugs (other psychoactive substances) as a 
group; or 
alcohol and other psychoactive substances (but 
not tobacco), respectively; or 
alcohol, tobacco and other psychoactive sub-
stances, respectively. 
Licit drugs such as prescribed medications and 
over-the-counter drugs, and volatile substances 
such as inhalants, are classes of psychoactive sub-
stances of epidemiological significance in many 
societies which have not been studied from an 
economic perspective. This would be a very valid 
and salient dimension of the substance abuse 
problem to analyze. Although the problems associ-
ated with misuse of licit drugs are not specifically 
addressed in these guidelines, they nevertheless 
present a valid and salient dimension of the sub-
stance abuse problem appropriate for analysis. 
In situations where many persons use multiple 
psychoactive substances, it can be very difficult to 
develop estimates of the costs of particular sub-
stances. Good epidemiological and etiologic 
research should attempt to address this issue. 
However, the drugs and their patterns of use 
change continuously and rapidly, which makes it 
difficult to define and study consequences and 
costs associated with single substances. 
In addition to determining which substances to 
consider, the scope of the study may be restricted 
to a particular drug (e.g., heroin, cocaine, marijua-
na), a particular mode of drug consumption (e.g., 
injection, smoking or oral), or for different poten-
cies of substance (for any drugs under considera-
tion). For example, public policy is often directed 
at the legal issues of a particular substance, such 
as decriminalization of or increased legal sanctions 
for a substance such as marijuana or powder 
cocaine or "crack" cocaine; taxation on smokable 
versus oral tobacco products; and differential reg-
ulation of beer, wine and distilled spirits. In theory 
this should be possible, although it may be difficult 
in practice because of data limitations. 
The majority of economic cost studies have exam-
ined costs associated with the use and abuse of 
alcohol, tobacco and other drugs, respectively. 
Fewer studies have attempted to simultaneously 
analyze and compare the economic costs of multic 
pie types of substances, or particular drugs, mode 
of administration or different potencies. Most 
studies of particular substances acknowledge the 
importance of examining and comparing the costs 
of other types of substances, but adopt a sub-
stance-specific focus because of limitations in time, 
resources or available data, or for the highly prag-
matic reason that the funding source (often a gov-
ernment agency) has a substance-specific man-
date. In sum, which substances and patterns of 
use are studied is generally driven by the needs of 
the sponsoring agency and the limitations of the 
data. 
Each of the broad drug groups-tobacco, alcohol 
and illicit drugs-has particular problems associat-
ed with its cost estimation. Of these groups, the 
most straightforward for cost estimation is tobac-
co. Tobacco is invariably taxed in virtually all coun-
tries, resulting in reasonable records of sales and 
presumably consumption (often verified by house-
hold surveys). Morbidity and mortality data associ-
ated with smoking have been steadily accumulat-
ed and improving in quality and quantity. A num-
ber of countries have developed etiological frac-
tions that provide an important tool for calculation 
and subsequent costing of tobacco-related illness-
es and deaths. A further important factor in cost-
ing studies is that almost all tobacco consumption 
diminishes the health status of the user, and of 
others subjected to tobacco smoke and therefore 
does not require calculation of dangerous, neutral 
or beneficial levels of consumption. Tobacco stud-
ies are therefore generally able to be both rigorous 
and comprehensive. 
The calculation of alcohol-related harm and con-
comitant costs is more complex, as some alcohol 
consumption causes harm, some is neutral and 
some is beneficial. Epidemiological work has pro-
vided the basis for calculation of benefits associat-
ed with alcohol consumption and for the health-
related effects of harmful consumption. However, 
much alcohol consumption is neutral and involves 
no social costs. The non-medical component of 
alcohol-related harm (e.g., impaired driving, vio-
lence and alcohol-related crime) can be measured, 
but requires the estimation of attribution factors 
indicating the proportion of such harm that can be 
causally linked to alcohol consumption. Total alco-
hol consumption is more difficult to measure than 
tobacco consumption, due to various sources of 
unrecorded consumption such as illicit production, 
legal home production, and assisted production in 
"U-brew" and "Make-your-own-wine" stores. 
The third group- illicit drugs- is the most com-
plex to cost and the least likely to be rigorously 
and comprehensively analysed. Due to the fact 
that these drugs are by definition illegal, there are 
no taxes and thus no tax records. Illicit drug users 
are reluctant to identify themselves as such and 
barriers are created for treatment. For all these 
reasons, data on illicit drug use are uneven, 
incomplete, unreliable and sometimes non-exis-
tent. Crime attribution factors are difficult to 
obtain. In developed countries some crime costs 
are available, and usually some health costs, but 
these are subject to attribution factors. 
Researchers are usually reliant on survey-based 
prevalence data in the absence of official statistics. 
Thus, recording systems provide a great deal more 
data on legal drugs such as alcohol and tobacco. 
However, in those countries where a significant 
proportion of alcohol and tobacco consumption 
stems from illicit importation or production, the 
estimation of alcohol and tobacco costs suffers 
from some of the same problems of data deficien-
cy that apply to illicit drugs. 
The use of psychoactive substances such as alcohol, 
tobacco and illicit drugs involves a numerous and 
varied set of adverse consequences. As indicated in 
Figure 2, there are four major types of costs that 
have been analyzed in economic cost estimates to 
date: (1) health care costs, (2) productivity costs, (3) 
costs to law enforcement and the criminal justice 
system, and (4) other costs such as property 
destruction from alcohol or drug attributable acci-
dents or crime. Some of these costs have been 
omitted from certain studies out of data limitations-
-not from disagreements about the theoretical cor-
rectness of including such costs. Each of these types 
of costs is discussed in the following sections with 
regard to the potential for being estimated, and of 
thereby being included in a cost estimation study. 
As indicated by the columns in Figure 2, costs may 
be tangible or intangible and the costs may be 
incurred by the individual user, other individuals, 
government or private industry. Intangible costs and 
the private costs to individual users are generally not 
included in cost estimation studies. 
Most studies on the costs of substance abuse have 
found the three largest types of costs to be produc-
tivity costs, health care costs and those costs relating 
to law enforcement and the criminal justice system, 
which is why the cost framework uses these major 
categories of costs. This is but one of a number of 
different ways to categorize these cost items. Some 
of the cost categories in Figure 2 refer to efforts to 
"prevent" substance abuse, some are due to crimi-
nal justice efforts designed to "deter" or to punish 
problematic involvement with psychoactive sub-
stances, while others are the costs associated with 
negative consequences of using psychoactive sub-
stances. There are certainly other classification 
schemes for these costs, and the articulation of new 
or alternative formats could suggest other approach-
es to cost estimation. 
It should also be remembered that the counterfac-
tual situation in Figure 2 is one in which there are 
FIGURE 2 -TYPES AND EXAMPLES OF COSTS ASSOCIATED WITH SUBSTANCE ABUSE 
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Premature mortality foregone taxes 
corporate research 
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net of taxes 
victims' forgone 
incomenet of taxes 
foregone taxes man's comp., 
productivity 
3. Law enforcement and criminal justice costs 
Criminal justice response penalties (e.g. fines) victim's time enforcement, court 
incarceration costs 
victim's time (productivi-
ty loss); criminal careers 
4. Other costs, e.g., property destruction 
unreimbursed property , 
damage 
(B) Intangible costs (not included in estimates) 
fire losses + accident 
damage to industry 
pain and suffering to, 
user quality life 
years lost 
suffering to dependents 
crime victims, + restric-
tions of public's legal 
rights to expedite 
no health or social problems associated with the 
use of alcohol, tobacco, licit or illicit drugs. The 
comparison of the actual situation to this counter-
factual scenario does not consider certain opportu-
nity costs which might be considered in different 
counterfactual situations. For example, if certain 
illicit drugs were made available via prescription or 
a government monopoly, there would undoubted-
ly be tax revenue for governments. Therefore 
some might consider lost tax revenue to be a 
"cost" of the current situation. However, the legal 
availability of these drugs is not the counterfactual 
situation in cost-of-illness studies, so forgone tax 
revenue is not considered a cost. In any case, tax 
revenue from drug sales simply represents a trans-
fer of resources from drug purchasers to the rest 
of the community. It does not create any more 
resources for the community as a whole- it simply 
redistributes existing resources. Thus a loss of rev-
enue cannot be a social cost, only a budgetary 
cost under a different counterfactual scenario. 
As seen in Figure 3, there are a wide variety of 
health problems associated with the use of alco-
hol, tobacco and illicit drugs. Some of these are 
entirely attributable to substance use, while other 
causes are only partly attributable. The proportion 
of, say, liver cirrhosis deaths or traffic accident 
injuries, which can be reasonably be attributed to 
alcohol use will vary between societies and over 
time within the same society. Therefore the choice 
of the appropriate attributable fraction depends on 
reviewing the most current literature on each par-
ticular cause of morbidity and mortality. There is 
no one set of attributable fractions that can be 
applied in any society. 
Regardless of how the various economic costs are 
classified, these are costs in the simplest economic 
FIGURE 3- SOCIAL COSTS ASSOCIATED WITH SUBSTANCE ABUSE WITH EXAMPLES 
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1. Consequences to health 
and welfare system 
Treatment for substance 
abuse: hospital costs, physi-
cian fees, costs of medication 
+other health costs multi-
plied by appropriate attribut-
able fraction 
Prevention, research and 
health services 
2. Productivity costs: conse-
quences to the workplace 
*Premature mortality 
Lost employment or 
productivity 
3. Law enforcement and crimi-
nal justice costs 
Criminal justice response 
(including drug related crime) 
4. Other costs, e.g., property 
destruction 
ith the use of 
Alcohol 
100% attributable to alcohol 
use: alcoholic psychosis, alco-
hol dependence, alcohol 
abuse, alcoholic polyneuropa-
thy, alcoholic cardiomiopathy, 
alcoholic gastritis, alcoholic 
liver cirrhosis, ethanol toxicity, 
methanol toxicity, other alco-
hol poisonings 
partly attributable to alcohol: 
lip cancer, oral cancer, pharyn-
geal cancer, oesophageal can-
cer, colon cancer, rectal cancer, 
hepatic cancer, pancreatic can-
cer, laryngeal cancer, breast 
cancer, pellagra, hypertension, 
ischaemic heart disease, car-
diac dyrshythmias, heart fail-
ure, stroke, oesophageal 
varices, gastro-oesophageal 
haem., cholelithiasis, acute 
pancreatitis, low birthweight, 
road injuries, fall injuries, fire 
injuries, drowning, aspiration, 
machine injuries, suicide, 
assault, child abuse 
Research, training, dependent 
welfare costs 





Enforcement, court + incarcer-
ation costs; criminal career 
costs 
Fire losses + accident damage, 
accident and fire prevention 
Tobacco 
100% attributed to tobacco: 
tobacco abuse 
partly attributed to tobacco: 
respiratory TB, lip cancer, oral 
cancer, pharyngeal cancern, 
oesophageal cancer, gastric 
cancer, pancreatic cancer, 
larngeal cancer, lung cancer, 
bladder cancer, renal parenchy-
mal cancer, renal pelvic cancer, 
respiratory carcinoma-in-situ, 
Parkinson's disease, ischaemic 
heart disease, pulmonarycircu-
latory disease, cardiac dys-
rhythmias, heart failure, stroke, 
atherosclerosis, peripheral vas-
cular disease, phenumonia and 
influenza, chronic bronchitis, 
peptic ulcer! ulcerative colitis, 
low birthweight, sudden infant 
death syndrome, fire injuries 
Research, training, dependent 
welfare costs 






ation costs; criminal career 
costs 
Fire losses + accident damage, 
accident and fire prevention 
Other drugs 
100% attributed to drugs: opi-
oid dependence, opiate non-
dependent abuse, opioid acci-
dental poisoning, opioid cause 
suicide, other opioid poison-
ings, barbiturate dependence, 
barbiturate non-dependent 
abuse, barbiturate accidental 
poisoning, barbiturate suicide, 
other barbiturate poisonings, 
other drug dependence, other 
drug non-dependent abuse, 
other drug accidental poison-
ing, other drug suicide, other 
drug poisonings, drug psy-
chosis, maternal drug depen-
dence, newborn drug toxicity 
partly attributed to drugs: viral 
hepatitis, infective endocarditis, 
opiate caused low birthweight, 
HIV/AIDS 
Research, training, dependent 
welfare costs 






ation costs; criminal career 
costs 
conception, recording the first instance of realloca-
tion of resources in the economy. The key aspect 
of these costs is that either goods or services are 
used or delivered (direct costs) or human produc-
tivity is lost or impaired (indirect costs) due to an 
individual's use of psychoactive substances.14 
Figure 3 does not distinguish between licit and 
illicit drugs. While desirable, it is very difficult to 
make this distinction because coding systems (the 
International Classification of Diseases, Version 9) 
do not distinguish problems due to licit or illicit 
drugs. For many categories, both licit and illicit 
drug problems are recorded in the same category. 
The availability of data to estimate the following 
costs and concepts is often related to how clearly 
a particular type of consequence is related to sub-
stance abuse. In many cases particular services or 
problems are definitely recorded in administrative 
records as due to or related to substance abuse. 
Making estimates of such costs depends on gain-
ing access to these data, and development of esti-
mates will thereby be more direct and understand-
able to both the analyst and the ultimate user of 
the estimates. However, many adverse conse-
quences arise from multiple causes in which sub-
stance abuse may or may not play a role. The ana-
lytic challenge is to obtain data that will provide a 
plausible basis for attributing some proportion of 
the costs associated with the particular negative 
consequence to substance abuse (the attribution 
factor). 
The following discussion focuses on whether there 
are likely to be sufficient data to produce robust 
estimates of the major categories of costs associat-
ed with substance abuse. It does not attempt to 
detail all of the more specific costs within each 
major category of costs associated with substance 
abuse. The specific problems and their associated 
costs will vary according to substance- alcohol, 
tobacco and other drugs have different problems 
associated with their use. 
Furthermore, the extent to which a particular con-
sequence can be attributed to the use of, say, 
alcohol will vary according to setting, both for epi-
demiological reasons and due to variations in the 
institutional arrangements for dealing with adverse 
consequences. Thus, for example, the proportion 
of liver cirrhosis that can be attributed to alcohol 
will be strongly influenced by the rate of alcohol 
consumption in a society, patterns of drinking and 
the availability of treatment. 
The establishment of the most appropriate attribu-
tion factors for alcohol and other drug related ill-
nesses and social problems therefore requires 
detailed literature reviews for each consequence. 
See, for example, Holman and Armstrong's review 
of the appropriate aetiologic fractions for alcohol, 
tobacco and illicit drugs (Holman and Armstrong, 
1990). Although such reviews do exist, the appro-
priate attribution factors conducted in one country 
may not be applicable to another country or even 
the same country at a different point in time. 
Therefore, the conduct of a cost estimation study 
on substance abuse requires careful line-by-line 
consideration of the specific costs to include and 
the attribution factors for each cost which are the 
most appropriate for the society in which they 
applied. 
A further caveat regarding the following discussion 
of major cost categories is that it does not specifi-
cally address issues and methodologies for assign-
ing values to indirect losses including premature 
mortality, morbidity and reduced productivity, 
crime victims' loss of work, incarceration and 
crime career losses. Studies tend to value losses of 
productivity using wage rates or replacement costs 
(for one's own business or for household produc-
tivity), with different values for individuals of dif-
ferent ages and genders. These issues are taken up 
in Section 4. The major objective of this section is 
to outline potential types of data sources and 
related analytic issues for each of the major types 
of costs in Figures 2 and 3. 
4.3.1 Treatment for substance abuse 
This category of costs should generally have some 
of the most readily available data (although not 
necessarily comprehensive) about services deliv-
ered due to substance abuse. There are two rea-
sons for this. First, some nations have identified 
publicly supported clinics that are dedicated to 
treatment of substance abusers. Therefore, there 
are government maintained data about the level 
of services and funding that are delivered through 
such service providers. 
Alternatively, many health care systems collect 
data about the health problems for which patients 
sought and received treatment from hospitals, if 
not clinics, physicians and other health providers 
that do not specialize in treating substance 
abusers. These data are often recorded using an 
internationally recognized coding system (the 
International Classification of Disease, or lCD) that 
define alcohol- and drug-related diagnoses, 
including: 
dependence on alcohol or drugs; 
abuse of alcohol or drugs; 
psychosis due to alcohol or drug use; and 
poisoning or overdose from use of alcohol or 
drugs. 
Thus a treatment episode or service received from 
a health provider can often be linked definitively 
to a substance abuse-related diagnosis and unam-
biguously attributed to substance abuse. 
In the absence of system-level data that track the 
causes for which medical care is delivered (e.g., 
Holman and Armstrong, 1990), the analyst will 
have to find "special studies" that would provide 
credible estimates of these values. For example, 
particular hospitals or clinics might perform studies 
of what disorders were treated, and how much 
care they required. Judgment will have to be exer-
cised in extrapolating such estimates to the entire 
system. For example, data from a "teaching" hos-
pital that serves as a referral centre may not be 
typical of care delivered in many other hospitals, 
and it would be useful to be able to make adjust-
ments to the data in order to address what may 
be known differences. 
4.3.2 Treatment for co-morbidity and trauma 
Excessive use of alcohol and drugs has been linked 
to numerous health problems, including, e.g., cir-
rhosis of the liver, nutritional and metabolic disor-
ders, infection with HIV, motor vehicle and other 
types of trauma, and some mental disorders (see 
Figure 3). There are two challenges for the analyst 
in developing estimates of the costs attributable to 
substance abuse. First, it is necessary to estimate 
health expenditures related to these health prob-
lems. Then, it is necessary to develop estimates of 
the proportion of these costs that are plausibly 
attributable to substance abuse. 
The ability to perform the first step depends on 
the development of data systems in a national 
health system. Again, where system-level studies 
have examined the level of services related to par-
ticular health problems using a comprehensive 
coding system (the lCD) it will be more possible to 
develop cost estimates for particular diagnoses 
(e.g., cirrhosis of the liver, or HIV infection). 
Without representative studies the analyst will 
need to make recourse to special studies (e.g., 
from a sample of health care providers) that must 
be used with caution. 
The other major challenge in developing these 
estimates is to estimate the proportion of costs for 
a particular health problem that are attributable to 
substance abuse. It is rare that standard data sys-
tems would have the necessary data for this pur-
pose. Studies in the United States of America find 
that medical records and data systems generally 
do not record whether or not a patient had an 
underlying substance abuse disorder that is likely 
to have caused the "presenting" health problem. 
Indeed, the analyst will need to identify special 
studies that have examined the underlying causes 
of particular problems, collecting detailed epidemi-
ological information and undertaking analyses that 
attempt to identify the causal roles of various "risk 
factors". 
The determination of attributable risk is particular-
ly complicated for those disorders that relate to 
consumption in a curvilinear fashion. For example, 
coronary heart disease is lower among low-level 
drinkers than among abstainers. Due to this "J" 
shaped relationship between alcohol consumption 
and coronary heart disease, alcohol both causes 
and prevents morbidity and mortality. Economic 
cost estimates can subtract out the number of 
cases prevented, and thus present a net effect of 
alcohol on the number of hospitalizations or 
deaths due to coronary heart disease. 
Alternatively, the analyst may choose to ignore the 
number of cases prevented by low level consump-
tion and present only the gross number of hospi-
talizations or deaths, on the grounds that a cost 
study should not give incomplete, partial consider-
ation to benefits associated with alcohol consump-
tion. 
In estimating an "attributable risk" factor the ana-
lyst should carefully assess the rigor and depth of 
the research literature that is available on the role 
of substance abuse in a particular disorder. Studies 
of simple "association" (for example, the propor-
tion of tuberculosis victims that were drug users) 
are not adequate for this purpose. They probably 
constitute the absolute upper limit of the role of 
substance abuse. Rigorous analysis will identify 
and adjust for the role of additional risk factors, 
and will almost always yield a lower "attribution 
factor" than the simple measure of association. 
Also, better studies of attributable risk will use rig-
orous statistical standards in identifying whether or 
not risk factors (including substance abuse) are 
causally related to the health problem under study. 
It should be emphasized that there is no single 
analytic methodology that is most appropriate for 
undertaking causal analysis. There are a variety of 
"study designs" and methodologies that can pro-
duce useful information. 
Attribution of mental illness to substance abuse is 
a perfect example of this challenge. Studies of 
drug and alcohol dependent individuals that are 
getting substance abuse treatment often find that 
up to a half of these individuals meet clinical crite-
ria for various mental disorders ranging from 
depression, to schizophrenia. Likewise, studies of 
the mentally ill find that material proportions have 
substance abuse problems. 
However, there is uncertainty about the causal 
relationship of the two types of disorders. Some 
research shows that mentally ill individuals initiate 
or escalate drinking and drug taking presumably 
to "self medicate" their disorder. Yet other 
research finds that alcohol and drug abusers 
develop symptoms of certain mental disorders 
(e.g., depression, anxiety, psychosis) as their sub-
stance disorder becomes more severe, when they 
abuse particular substances (alone or in combina-
tion) or when they attempt to stop using or 
detoxify. The challenge in developing attributable 
risk" factors for mental disorders (and for the costs 
of treating mental disorders) is to estimate how 
much of the treatment for mental disorders is 
caused by substance abuse-not simply associated 
with substance abuse. If an already severely men-
tally ill individual develops a substance abuse dis-
order, the additional care that such an individual 
requires should be attributable to substance abuse, 
however the expected care for the mental disorder 
apart from the substance abuse problem would 
not be attributable. 
In most COl studies estimating the costs of sub-
stance abuse, the largest cost involves lost produc-
tivity due to premature death, disability, absen-
teeism and other causes of lower productivity on 
the job. Estimation of productivity costs requires, 
first and foremost, robust estimates of premature 
mortality and morbidity that can be attributed to 
substance abuse. 
4.4.1 Premature mortality 
National health systems view data about mortality 
as quite valuable in monitoring the health of the 
populace. Often mortality data (deaths for one or 
more year) are centrally collected, with informa-
tion about the cause of death and demographic 
characteristics of the decedent. Cause of death 
can be coded for purposes of analysis using the 
lCD system. As noted above, there are identified 
lCD substance abuse-related codes that can be 
associated with deaths. When national mortality 
data are collected and processed in this form it 
makes the task of the analyst relatively straightfor-
ward in assembling data on deaths with a direct 
link to substance abuse. 
However, substance abuse can also cause death 
indirectly, as discussed above under "Health 
Treatment for Comorbidities and Trauma". As 
indicated previously, the challenge to the analyst is 
to first identify causes of death for which there is 
research substantiating a causal role for substance 
abuse, to obtain the data on mortality for the 
year(s) of concern related to that cause, and then 
to develop and estimate of the proportion of 
deaths that are attributed to substance abuse. The 
same analytic issues apply to studies of mortality 
as to studies of health care utilization. Greater 
reliance should be put on more "rigorous" studies. 
Studies of "association" should be eschewed in 
favor of studies analyzing the contribution of mul-
tiple risk factors that apply standard statistical cri-
teria to the analysis. 
4.4.2 Morbidity - lost employment or productivity 
There are real economic losses associated with ill-
ness-caused lost days of work (in paid employ-
ment, in one's own business such as agriculture, 
and in household productivity), and with work 
performed (in any of these venues) by those that 
have long-term or short-term impairments or dis-
abilities. Measuring and attaching values to these 
phenomena is quite challenging for many of the 
same issues that must be addressed in estimating 
health care resources used to address substance 
abuse. This discussion does not address issues pri-
marily related to valuation of lost or impaired work 
time, such as what is the unemployment rate in 
the nation under study. These estimates should be 
understood to represent lost or reduced "poten-
tial" work time/productivity. 
The first type of data concerns work time missed 
due to participation in treatment. Residential, hos-
pital and "day treatment" patients usually miss 
work, and to the extent that data exist on care 
delivered in such settings it is possible to develop 
basic estimates of lost work time. Similarly, partici-
pation in ambulatory or outpatient treatment may 
entail some time away from work to receive treat-
ment, and this estimate can be constructed with 
data on enrollment in outpatient treatment. These 
data should also include information about the 
demographic characteristics of the patients, in 
order to make adjustments for the "expected" 
level of employment/productivity. 
Another source of data would come from esti-
mates of patient time spent in hospital and ambu-
latory health care for health problems caused by 
substance abuse. This would build on the same 
analytic literature and data used to make estimates 
for health care services above. 
A further source of data for this estimate would be 
from studies of health and employment. For 
example, health surveys in the United States of 
America ask about health status, loss of work due 
to health problems, and the nature of those prob-
lems. Health problems are coded for analysis using 
the lCD system, and data can be assembled on 
diagnoses that are directly coded as substance 
abuse, and for health problems/diagnoses that 
have been established as related to/caused by 
substance abuse in the epidemiological and etio-
logic literature. 
Prior studies have found that the largest part of 
morbidity/lost and reduced productivity costs is 
not due to measurable lost days of work, but from 
impaired productivity while on the job. Numerous 
studies have found that many substance abusers 
hold jobs. There is a smaller, but growing literature 
that has yielded evidence that substance abusers 
are less productive in their jobs than individuals 
with otherwise similar experience and capabilities. 
Such studies use labour economics models to ana-
lyze"general population" surveys that contain 
standard labour market information as well as 
information about use of and problems associated 
with psychoactive substances. The objective of 
such an analysis is to use statistical analysis to 
identify patterns of substance use or problems that 
are associated with employment and earnings 
deficits, standardizing or controlling for the other 
characteristics of substance abusers. These esti-
mates are then applied to estimates of the propor-
tion of the population (employed and otherwise) 
that have these patterns of use or problems, and 
then to assign economic values to the identified 
deficits. 
It is widely recognized that substance abuse by 
workers can adversely affect their performance 
and the productivity of the workplace. However, 
there is a major theoretical and empirical problem 
when one attempts to estimate the cost of sub-
stance abuse on the workplace. The effect of 
employers operating in markets for labour, other 
inputs, capital and wages for goods and services 
serves to spread the impacts between the employ-
ers (lost profits), the workers (lost earnings and 
benefits) and consumers (higher prices for goods 
and services). The distribution of costs between 
these parties can not be determined solely by · 
using economic theory, since the outcome is partly 
determined by market conditions and, in particu-
lar, by the relative bargaining abilities of employ-
ers, workers, and consumers. 
In theory, the value of workers to the employer is 
determined by calculating the amount that they 
work times the value of their productivity when 
they work. In a perfectly functioning labour mar-
ket, workers' wages are expected to equal the 
value of their productivity to the enterprise. 
Earnings are by definition the amount of time 
worked times the wages paid per amount of time. 
Substance abuse by workers can affect both the 
amount of time that they work (e.g., missed time 
due to absenteeism, tardiness, excess sickness) and 
their productivity when they are at work (e.g., 
lower quality of their efforts, costs of mistakes 
caused by substance misuse). It is also emphasized 
that worker problems can adversely impact the 
productivity of co-workers and managers, as well 
as morale in the workplace when other employees 
must work harder or otherwise deal with problems 
caused by substance misuse. 
If the labour market were working perfectly, any 
reduction in productivity resulting from the work-
er's substance abuse would result in a reduction in 
the wages that the employer was willing to pay 
that worker. This type of analysis has lead some 
economists to conclude that the costs of substance 
abuse by workers are borne by the workers them-
selves in the form of lower wages. Thus, this line 
of reasoning concludes, these costs are private 
costs borne by the workers, not social costs borne 
by the rest of the community. 
This analysis also implicitly assumes that the work-
ers have made rational and fully informed deci-
sions to become substance abusers, in most cases 
a dubious assumption. An even more serious 
problem affecting the above conclusion is the 
underlying assumption that labour markets func-
tion perfectly so that virtually automatic wage or 
salary adjustments occur as a result of productivity 
declines caused by substance abuse. In practice, 
the validity of this assumption depends very much 
upon the institutional and other characteristics of 
the country for which the cost estimates are being 
made. Labour markets may not work perfectly for 
a variety of reasons: 
Employers may not recognise the abuse-associ-
ated costs which they are bearing. 
Wages may not be flexible downwards for insti-
tutional reasons. For example, Australia has a 
system of award rates and conditions which 
drastically reduces the scope of downward flexi-
bility. 
Unfair dismissal legislation may make it difficult 
to dismiss less productive workers. 
The abusers may be employed in the public sec-
tor where wage flexibility may be much lower 
and dismissal procedures much more cumber-
some. 
The abusers may be employed by companies 
which have organisational slack (that is, have 
not minimised costs for their chosen output lev-
els) and which have the ability to pass on higher 
costs to their customers in the form of higher 
prices. Markets may not be sufficiently competi-
tive to ensure that firms with organisational slack 
will ultimately fail. 
To summarise, only where labour markets are 
functioning perfectly will substance abuse-attribut-
able production costs be totally private costs 
(assuming that the other necessary conditions are 
also met). Analysis of the incidence of workplace 
costs (that is, in which sector(s) those costs are 
borne) requires that serious attention should be 
paid to the institutional characteristics of the rele-
vant labour market. 
This type of costs applies primarily to" health-relat-
ed" impacts on employment. As will be discussed 
later, substance abuse has other avenues through 
which it appears to impact on labour market per-
formance and productivity - mainly related to 
criminal activities and incarceration of criminals. 
4.4.3 Treatment of non-workforce mortality and 
morbidity 
The valuation of production lost as a result of sub-
stance use could be taken to be the value of 
wages forgone, on the basis that wages are equal 
to the worker's productivity (this value is often 
taken to be average earnings) or on the basis of 
some estimate of average gross domestic product 
per worker. However, this approach to costing is 
unsatisfactory because it does not assign any value 
to the unemployed, the retired or women outside 
the paid workforce, since they do not earn wages 
or salaries. People not in paid employment may 
well be contributing output but it is unpaid work, 
and so its value is not incorporated in conventional 
measures of national output 
This issue can be clarified by use of the distinction 
between tangible and intangible costs. There will 
be no loss of paid output as a result of morbidity 
or mortality of the unemployed, the retired, chil-
dren, students, parents at home looking after chil-
dren, or other people not in the workforce but 
there will be a value of lost unpaid work, as well 
as the loss of life incurred by these people them-
selves. There will also be a loss of unpaid work as 
a result of deaths of the employed but, according 
to available evidence, this loss will on average be 
less than for. the rest of the adult population. The 
deaths of both employed and unemployed/out-of-
the-work-force will impose a social cost but the 
cost will be greater for the employed. This point is 
illustrated in Figure 4. 
In summary, for the employed the net cost is the 
loss of paid output plus the loss of unpaid output 
plus the value of life. For the unemployed or peo-
ple out of the work force, the net cost is the loss 
of unpaid output plus the value of life. This analy-
sis clearly disposes of the suggestion that society 
FIGURE 4: THEORETICAL IMPACT OF PREMATURE MORTALITY 
Death of ! Tangible cost 
Employed Loss of paid output 
4 Loss of unpaid output 
Unemployed o Loss of unpaid output 
or out of work 
incurs no cost as a result of the premature deaths 
of the unemployed or people out of the work 
force. 
Estimates of the value of unpaid work place a 
value on these activities that could have been 
replaced by an equivalent service purchased from 
an outside source. For, example, the child-minding 
activities of"non-working" mothers might be 
replaced by hired nannies. The types of activities 
to be considered here are domestic activities, 
childcare, purchasing of goods and services, and 
volunteer and community work. The sickness or 
death of people engaged in such activities will 
involve withdrawal of others from the workforce 
to maintain the supply of non-market services. 
Value can be placed on these activities by estimat-
ing the cost of hiring a market replacement for 
each individual function. In this way the important 
issue of the value of productivity of married 
women in the family home is satisfactorily han-
dled. 
The use of average earnings to indicate the value 
of the lost output of the employed implies that it 
represents the value of the output of the sick or 
prematurely dead. In practice, average earnings 
may be below the value of output because of 
labour market imperfections or because the work-
ers involved are not paid the full value of their 
output. In addition, weekly earnings as measured 
by national statisticians tend to omit some impor-
tant components of earnings, for example super-
annuation and fringe benefits, and the incomes of 
proprietors and partners of unincorporated busi-
i Tangible benefit ! Intangible cost Intangible benefit 
Reduction of Reduction of nil 
consumption consumption 
value of life 
Reduction of Reduction of nil 
consumption consumption 
value of life 
ness and of self-employed people. Adjustments 
should, therefore, be made for those other com-
ponents of income. 
4.5.1 Criminal justice expenditures 
As for health care expenditures, some criminal jus-
tice services are identifiably and by definition relat-
ed to use of psychoactive substances, while others 
are indirectly, although still causally related to use 
of psychoactive substances. One may think of 
three different types of cost estimation situations 
with respect to the various types of criminal justice 
services: criminal justice activities completely dedi-
cated to combat the consequences of use of psy-
choactive substances (such as a distinct alcohol or 
drug enforcement unit); activities by general crimi-
nal justice entities that address illegal use of psy-
choactive substances; and activities of general 
criminal justice entities to address crimes believed 
to be caused by use of psychoactive substances. 
Estimates can theoretically be developed for law 
enforcement authorities (police and prosecutors), 
courts, and corrections (prisons, jails, and commu-
nity supervision of offenders). 
Data on criminal justice units that are solely or 
predominantly dedicated to address illegal use of 
psychoactive substances can usually be obtained 
from government sources. These are the least 
ambiguous of the criminal justice costs, if such 
units exist and data are available. 
The greater challenge comes in analyzing costs 
from general criminal justice entities, particularly 
law enforcement and judicial services. It is very 
difficult to allocate effort and costs across the dif-
ferent missions of such entities. For law enforce-
ment there may be data about types and numbers 
of arrests, for example about infractions against 
alcoholic beverage laws, or drug control laws, 
respectively. These arrest data provide a first level 
to allocate effort and costs across various types of 
offences. However, this raises the question of how 
much effort and cost is involved with an arrest for 
each type of offence. Such data are likely to be 
unavailable, and it will probably be necessary to 
make and acknowledge simplifying assumptions 
about cost allocations. 
The most difficult cost estimates will involve mak-
ing attributions of the role of using psychoactive 
substances in other types of crime such as robbery, 
burglary, assault, prostitution and gambling. 
Mankind has spent eons contemplating why we 
break social norms (commit crimes), much atten-
tion is being given to the use of psychoactive sub-
stances. It should be sufficient to say that data 
about the proportion of offenders that were intox-
icated with alcohol or drugs when they committed 
a crime are only data about association, and pro-
vides circumspect information about causation. 
The analyst must be very careful and explicit in 
discussing how attribution factors are derived for 
such crimes. It may often come down to whether 
the analyst is willing to exercise their reasoned 
judgment and make an explicit assumption about 
the rate. If so, that assumption should be backed 
up by a chain of logic and the best data that are 
available. 
4.5.2 Crime victim's time losses 
A material, if relatively small, share of costs is 
derived from lost work experienced by crime vic-
tims. Estimates of this type of cost depend on hav-
ing data about the number of crimes experienced 
by victims per year, data about the amount of pro-
ductive work time lost due to a crime (at a job, 
one's own business, or in the household), and the 
proportion of various types of crimes that are 
attributed to use of psychoactive substances. 
Basic data about the number of crimes might be 
accumulated and reported by criminal justice 
authorities but it should be understood that these 
data are probably a dramatic underestimate of the 
amount of crime. Studies have shown that the 
largest proportion of crimes (e.g., assaults and 
theft) are never reported to criminal justice 
authorities by the victims. Studies of crime victims 
should be used to develop estimates of how many 
crimes are experienced and what level of work dis-
ruption is experienced. Such data usually come 
from the same studies that examine property loss 
and destruction associated with crime (see above). 
-------------------
This still requires the analyst to confront the issue 
of attribution of crimes to use of psychoactive 
substances. 
4.5.3 Incarceration 
When individuals are incarcerated they are often 
partially or totally removed from the productive 
economy. This constitutes a loss of potential pro-
ductivity to the economy. While this loss repre-
sents a conscious decision by society, deemed to 
be justified on the basis of protecting other citi-
zens and punishing offenders, it is nonetheless a 
withdrawal of a certain number of the populace 
from the possibility of participating in productive 
activities. This withdrawal, or loss, is reduced to 
the extent that prisoners engage in work while 
incarcerated, either for outside purposes, or to 
support the prison. 
Data about incarcerated populations (and the 
costs of operating those systems) should be more 
readily available and more reliable than data about 
law enforcement activities. Information should be 
collected about those that are incarcerated due to 
crimes defined as due to use of psychoactive sub-
stances (violations of alcohol beverage control 
laws, and use and trading in controlled sub-
stances) and crimes where there is some attribu-
tion role for psychoactive substances. In the latter 
case data on incarcerated persons should be 
obtained by type of offence, as the extent of 
involvement (and attribution) of psychoactive sub-
stances is likely to vary. 
One type of study that an analyst should seek in 
developing this estimate is a survey of prison 
inmates. Sometimes such studies undertake to 
analyze factors believed to be involved with crimi-
nal behaviours, included whether the individual 
has a history of use of psychoactive substances, or 
was using them at the time that they committed 
the crime for which they are incarcerated. As 
before, the analyst should attempt to arrive at 
estimates judged to reflect "causality" relying if 
possible on data and analysis, but always it will be 
necessary to use careful judgment. 
4.5.4 Crime career costs 
This is probably the most esoteric and ephemeral 
of the costs associated with use of psychoactive 
substances, and probably the most difficult to esti-
mate. The concept behind "crime career" costs is 
that some otherwise able-bodied and able-minded 
users of these substances "drop out" of the legal 
economy in order to produce or trade in psy-
choactive substances or to pursue income-gener-
ating crime because of the demands of their drug 
addiction. Thus there is a loss of potential produc-
tion in the legitimate economy. 
It is extremely challenging to estimate this cost 
component, and it would be an understatement to 
say that the estimates would have poor statistical 
reliability. This estimate would probably have little 
or no statistical properties because the estimates 
used for this cost may have to be based on expert 
judgments and informed opinions. There have 
been few studies that have produced statistically 
rigorous and plausible estimates of the size of this 
population. 
Data of some nature may exist for various parts of 
this population, such as addicts seeking treatment 
or health care, or drug users and traffickers that 
are arrested. Such data can be combined to gener-
ate lower-bound estimates of the size of the popu-
lation under discussion, however, anthropological 
studies of this population find that a surprisingly 
large proportion of addicts have never been in 
treatment, sought health care, or arrested. Also, 
studies have attempted to use sophisticated statis-
tical inferential techniques to indirectly estimate 
the size of the population (for example, the cap-
ture-recapture model, and epidemiological models 
of transmission of HIV infection among injection 
drug users). 
The analyst may need to search extensively in 
order to develop such estimates. Ultimately it will 
become a question of judgment about which data 
to use, if any, and how to combine estimates from 
disparate sources. The most meaningful test for 
this estimate, if it is developed, is whether it is 
judged to be credible- not statistically rigorous-
by those who have carefully studied the problem 
from various perspectives. 
4.6.1 Treatment of research, education and law 
enforcement costs 
Some costs that are clearly attributable to sub-
stance use result from public decisions to reduce 
abuse rather than being the direct effects of sub-
stance use. Costs in this category include expendi-
tures on research on the impact of substance use, 
public education campaigns to minimize use or 
abuse, and law enforcement programs to reduce 
illegal dealing and use. These costs are discre-
tionary in the sense that governments could 
choose not to incur them, or, indeed, to incur 
higher levels. It is to be expected that reduced 
expenditures would lead to higher direct costs of 
substance use but these expenditures are, never-
theless, not themselves direct costs. 
It is appropriate to indicate the level of social costs 
incurred in these expenditure areas but to catego-
rize them as "policy costs" rather than direct 
costs. They are, in this way, identified as being 
incurred in relation to substance use but are not 
classified as unavoidable costs of use. 
4.6.2 Prevention and other public health efforts 
The primary source of data on this item will gener-
ally be from government budgets. Many of these 
services are in the form of media messages, edu-
cational efforts and materials. However, other ser-
vices and activities are also considered to be useful 
in combating substance abuse, such as after 
school activities for adolescents, and interventions 
with youth at risk of school drop out of failure. 
Consequently, funding of these services may be 
motivated by the substance abuse problem and 
therefore recorded as part of the effort to address 
substance abuse. However, the 1994 First 
International Symposium on Estimating the Social 
and Economic Costs of Substance Abuse recom-
mended that these costs should be recorded as 
discretionary policy costs rather than as unavoid-
able costs of substance abuse, because the coun-
terfactual is likely to have them continue, after the 
abuse is reduced or even ceased. 
4.6.3 Property destruction or losses due to crime 
or accidents 
The inclusion of the cost of property destroyed or 
the reduction in value due to accidents caused by 
substance abuse is relatively uncontroversial. 
Property losses due to crime caused by substance 
abuse is somewhat more contentious. While the 
transfer of ownership via a theft is usually treated 
as an economic transfer and therefore not a cost 
to the economy as a whole, the stolen property 
typically has significant lower value than it had 
before it was stolen. In such cases, the cost evalu-
ation procedure should follow the local practice, 
i.e., take into account the fact that theft results in 
a reduction in value of property. This should be 
explicitly mentioned and the reduction in value of 
stolen property itemized in the cost calculations. 
There are two sets of data necessary to estimate 
the costs of property damage due to crime or acci-
dents caused by substance abuse. The first is data 
on the incidence and costs of such events, and the 
second is a set of estimates about the proportion 
of the national total that can be attributed to sub-
stance abuse (whichever substances are under 
examination). 
National data on total incidence and costs for 
these impacts will generally come from, respec-
tively, criminal justice system studies on the inci-
dence and nature of crime, and from a system 
that tracks events such as motor vehicle crashes 
and fires. Both property and personal crime some-
times involve damage to and destruction of prop-
erty, although this value seems to be relatively 
small, compared to other costs associated with 
substance abuse. On the other hand, property 
damage from motor vehicle crashes, fires, other 
transportation accidents (train, air) can amount to 
sums orders of magnitude greater than that 
involved with crimes. These data may be either 
maintained in a regularly operating reporting sys-
tem (probably sponsored by a government 
agency), or collected through special studies per-
formed on an irregular basis. 
To complete these estimates there must be 
research on the involvement if not the causal role 
of substance abuse in the respective causes of 
property damage. While reporting systems on 
motor vehicle (and other transportation) crashes 
do increasingly assemble and report data about 
the involvement of alcohol and other psychoactive 
substances, this is less likely to be true for other 
causes of property damage. Accordingly, recourse 
will need to be made to the epidemiological litera-
ture for special studies of these problems with the 
general caveats for utilization of such studies. 
Note that it would generally not be appropriate to 
use attribution factors for one cause of damage to 
another. Different types of crime typically involve 
alcohol and other psychoactive substances to vary-
ing degrees, and the same has been found in 
motor vehicle crashes of different severity. Fatal 
motor vehicle crashes have generally been found 
to be much more likely to involve operator con-
sumption of alcohol than are non-fatal crashes. 
4.6.4 Welfare costs 
In dealing with the welfare costs attributable to 
drug abuse great care needs to be taken to distin-
guish between the real resource costs of abuse 
and costs which are simply pecuniary costs (i.e. 
transfer payments). The welfare costs dealt with 
here relate to the payments borne by the state 
(such as invalid pensions and sickness benefits). 
Relevant welfare payments are made to the vic-
tims of drug abuse, their carers and dependents. 
Welfare cost calculations should also incorporate 
some estimate of the proportion of the total 
administrative costs of the social welfare system 
that is attributable to substance abuse-related wel-
fare dependence. These administrative costs are 
real resource costs and should always be counted. 
It is important to ensure that there is no double 
counting of costs or benefits. If a person previous-
ly in the workforce receives welfare benefits as a 
result of abuse-related sickness it would be double 
counting to include in the estimate of social costs 
both the productivity loss and the direct cost of 
welfare benefits. The productivity loss is a real 
resource loss while the welfare payment simply 
represents a redistribution of consumption ability 
from the rest of the community to the abuser. 
However, if the abuser is rational and fully 
informed the private resource costs will be fully 
internalised and should not be counted as part of 
social costs. On the other hand, in these circum-
stances the welfare costs will represent an exter-
nality imposed on the rest of the community and 
should be incorporated in social costs. It is never 
correct to count both productivity and welfare 
costs. Which should be counted depends on the 
assumptions about the rationality of, and the 
amount of information available to, the abuser. All 
welfare costs should be incorporated in estimates 
of budgetary impact. In principle, drug abuse 
could lead either to increases or to decreases in 
welfare costs (because some people who die pre-






The International Guidelines present a methodolo-
gy that all nations may use to prepare estimates of 
the social costs of substance abuse. The applica-
tion of the methodology, however, requires exten-
sive data and information that many countries 
may not posses. 
There is strong interest in many nations, including 
developing nations, in understanding the nature 
and extent of the drug problem in all of its mani-
festations. For example, the 34 nations of the 
Western Hemisphere of the Americas have agreed 
to develop estimates of the social costs of sub-
stance abuse as part of the Organization of 
American States Multi-Evaluation Mechanism. 
International organizations like the WHO, UNDCP, 
and the EMCDDA are also participating in efforts 
to develop such estimates. While the methodolog-
ical approach provides a consistent framework for 
all nations to use, its application will be subject to 
tremendous variation due to cross-national data 
differences. Further confounding the successful 
application of the methodology is the fact that 
developing economies may have more difficulty 
using the methodology because of problems with 
their data infrastructure. 
The application of the methodology is challenging. 
The estimate of social costs is developed through a 
series of sub-estimates, each requiring specific 
data that all nations may not posses. As is high-
lighted below, data are required about the inci-
dence and prevalence of substance abuse, rates of 
addiction, mortality and morbidity, crime costs, 
health costs, and so forth. The problem of data 
availability raises a concern about the veracity of 
estimates when many of these data sources are 
unavailable. 
Developing countries are likely to face even more 
of a challenge in applying the methodology to 
estimate the social costs of substance abuse due to 
gaps in data. Decisions about investments in data 
infrastructure will likely take a back seat to more 
urgent social and economic needs. Such 
economies may need direction in developing long-
term strategies to select data systems that are 
within their means and best serve the needs of the 
methodology for estimating social costs. 
Developing countries may choose to selectively 
invest in data systems, hopefully procuring those 
data systems that offer the greatest advantages to 
the application of the methodology. Over the 
shorter term, developing countries will require 
other remedies to close the data gap for purposes 
of applying the methodology. These remedies 
range from setting the sub-estimate to zero (i.e., 
assume no cost attribution for the particular cost 
category), adopting estimates from external 
sources such as the experience of other nations in 
similar circumstances, to using rapid assessment 
methodologies. Where there is clearly insufficient 
data to conduct a COl study, another option is to 
undertake studies to estimate Disability Adjusted 
Life Years (DALYs) or Quality Adjusted Life Years 
(QALYs), thereby providing an epidemiological 
rather than an economic assessment of the burden 
of disease. 
The first question that any nation must address 
once it decides to estimate the social costs of sub-
stance abuse is whether data are available in suffi-
cient quantity to apply the methodology to pro-
duce robust estimates of the major categories of 
costs associated with drug abuse. A tentative list 
of the data required to carry out a cost estimation 
study is as follows: 
Data on population structure by age and gender, 
and life expectancy by age and gender. 
Data required to estimate morbidity and mortali-
ty: prevalence data on drug use and injection 
drug use; number of deaths and hospitalizations, 
ideally by cause, age and gender; list of condi-
tions which epidemiological research have 
shown to be attributable to drug use and the 
associated relative risks; estimates of the attrib-
utable fractions for certain causes of death and 
disease, based on local information, e.g., motor 
vehicle accidents, assaults, homicide, suicide. 
Health care costs: hospitalization costs, physician 
fees, costs of other professional services, and 
number of cases seen by physicians and other 
professional service providers by age and gen-
der; ambulance costs (total costs, total number 
of trips, number of trips for drug-related causes); 
costs of pharmaceuticals used to treat drug-
related conditions (total number of prescriptions, 
number of prescriptions by cause). 
Policy costs: police, court and corrections costs; 
expenditures on prevention and research related 
to drugs; costs of training for physicians, nurses 
other health professionals, law enforcement. 
Costs of Employee Assistance Programmes and 
estimates of the proportion of such costs attrib-
utable to drugs. 
Indirect productivity costs: mean income by age 
and gender (to estimate morbidity costs) and 
present value of lifetime earnings by age and 
gender (to estimate costs of premature mortali-
ty). 
The key issues for each of these data domains are 
whether data are available, in what form and from 
what source. Hopefully, some of these data will be 
collected from national censuses, surveys, or spe-
cial population studies. In some cases, the infor-
mation may not be available from formal surveys, 
but may be available in administrative records. 
Making estimates of such costs depends on gain-
ing access to these data. The analytic challenge is 
to obtain data that will provide a plausible basis 
for attributing some proportion of the costs associ-
ated with the particular negative consequence to 
drug abuse. In other cases, data may not be avail-
able from any source. In such cases, a nation may 
wish to engage the use of rapid assessment 
methodologies or other means to fill the informa-
tion gap. 
In an ideal world, the data required to apply the 
methodology for estimating the social costs of 
substance abuse would be available to every 
nation. In reality, few nations possess such a 
wealth of data, which means that short-term solu-
tions will be required. 
One approach gaining popularity is the use of 
rapid assessment tools being developed by the 
WHO and other international agencies to gather 
data in particular topical areas. Another approach 
is to conduct special evaluations to provide plausi-
ble estimates of a component of the calculation of 
social costs. This is particularly useful to the chal-
lenge of attributing some proportion of the costs 
associated with the particular negative conse-
quence to drug abuse (the attribution factor). 
For some categories of social costs, a nation may 
be unable to obtain any information from any 
internal source. Rather than ignore the calculation 
of a sub-estimate, they may seek information for 
sub-estimates from external sources, defined here 
to represent information from other nations with 
similar situations or problems. External information 
can provide reasonable estimates of categories of 
costs while a longer-term data strategy is imple-
mented. For example, until internal studies are 
available, it may be better to use the proportion of 
crime attributable to substance abuse in another 
(preferably, similar) country rather than ignore a 
potentially important cost element. 
Interpretation of 
cost estimates and 
the relevance 
to evaluation of 
policies and 
programmes 
Evaluation of policies and programs designed to 
reduce substance abuse is essential to inform pub-
lic policy. There is a tendency to give considerable 
attention to the aggregate total cost estimates in 
COl studies. While the bottom-line figures are 
useful for setting policy agendas, it was noted ear-
lier (see Section 1.2) that this is but one of several 
purposes to cost estimation studies. Equally impor-
tant is economic evaluation, to ensure that 
resources are used appropriately. The estimation of 
the economic and social costs of substance abuse 
provides tools for economic evaluation of policies 
and programs. 
It was noted earlier in Section 2.6 that the inter-
pretation of cost estimate results depends in part 
on whether productivity losses are estimated using 
a human capital or a demographic approach as 
these two approaches are intended to address 
somewhat different research questions. In either 
case, aggregate estimates of the social costs of 
substance abuse are not designed to indicate the 
benefits that would be realised by effective pre-
vention and harm reduction programs since: 
Some of these costs relate to past substance 
abuse (for example, smoking-attributable mor-
bidity). These are, therefore, unavoidable costs. 
It would be unrealistic to expect the complete 
elimination of the abuse of any particular sub-
stance. Even for periods well into the future, 
when the effects of past abuse have washed out 
of the system, it may be possible to reduce the 
costs of substance abuse but certainly not to 
eliminate them completely. 
Thus it is necessary to estimate the avoidable costs 
of substance abuse, in order to be able to indicate 
the extent of potential returns to harm minimisa-
tion programs. However, estimates of avoidable 
costs fail to indicate how these cost reductions 
might be achieved or whether the social benefits 
resulting from these programs would exceed their 
social costs. These issues can only be settled by a 
process of project appraisal. 
Project appraisal evaluates the efficiency of alter-
native projects or alternative policies. Its aims are 
to determine, by a process of enumeration of the 
benefits and costs of alternative projects or poli-
cies, the appropriate level of public resources to be 
devoted to the problem and the particular solu-
tions to which those resources should be devoted. 
Its objective is to maximise the social rate of return 
resulting from the use of public resources so that 
these resources can be used as efficiently as possi-
ble. 
The viewpoint from which project appraisal is 
approached is that of the community as a whole, 
not of individuals, firms or the public sector. This 
social perspective complicates the analysis sub-
stantially since private project appraisal avoids 
many of the theoretical and practical difficulties 
that social appraisers must confront, valuation of 
benefits and choice of discount rate being two of 
the most important. Furthermore, since the view-
point is that of the community as a whole, not just 
of the government, the issues are much more 
complex than those of public expenditure funding 
and public revenue benefits. 
In principle, the process of project appraisal should 
lead to the allocation of resources to programs 
that yield at least a minimum test rate of return. 
This rate of return should take account of rates of 
return, calculated on a consistent basis, on invest-
ment in the private sector in order to ensure an 
efficient allocation of resources between private 
and public sectors. In practice, there are many 
types of public goods and services that the private 
sector is unlikely to ever supply (unless through 
private provision facilitated by public funding). 
Even if it were possible to calculate public and pri-
vate rates of return on this consistent basis, there 
are political constraints on public expenditure lev-
els. Consequently, the objective of project 
appraisal is usually to achieve the efficient alloca-
tion of previously determined public expenditure 
levels between competing public sector uses. 
Governments generally purport to be attempting 
to reduce the size of the public sector, on the 
grounds that private expenditures are more effi-
cient than public expenditures. At this level of 
evaluation the appropriate evaluation tool is bene-
fit-cost analysis (BCA). 
The scope of project appraisal can be extended 
into program budgeting, which is a system of 
managing government expenditures by attempting 
to compare the program proposals of all govern-
ment agencies authorised to achieve similar objec-
tives (Hyman, 1996). 
In many cases the objectives of public expenditure 
analysis may be even more modest. The objective 
of the evaluation exercise may be predetermined 
(for example, a reduction of ten per cent in juve-
nile smoking prevalence) so that the analysis is 
reduced to cost comparisons of alternative pro-
grams designed to achieve the same objective. In 
other situations it may be considered that it is so 
difficult to value a program's output so that BCA is 
impossible. In these circumstances cost-effective-
ness analysis (CEA) is appropriate. A disadvantage 
of COl studies is that the results are not easily 
linked to the outcome of interventions. Even a 
state-of-the-art COl study does not provide an 
adequate basis for resource allocation. The WHO 
has produced resource documents on CEA that 
can assist in linking the costs of health care inter-
ventions to summary measures of population 
health outcomes such as DALYs (see, e.g., Murray 
et al., 2000). 
CEA can be defined as a detailed comparison of 
the costs of alternative techniques for achieving 
the same predetermined objective. In practice, 
CEA can be used to determine how a given objec-
tive can be achieved at least cost or how a desired 
output can be maximised for a given cost. The 
objectives and the outputs of programs subject to 
CEA are almost always one-dimensional since, if 
alternative programs yield multiple outputs in dif-
ferent ratios, it becomes necessary to assign values 
to each type of output. 
The advantage of CEA in its usual, more limited 
sense is that there is no need to value output ben-
efits. This makes the analysis much simpler than 
BCA since it is necessary to identify only the costs 
of alternative interventions. This is generally a 
much more straightforward process than valuation 
of program benefits, even though significant prob-
lems may arise in the allocation of overhead costs. 
The major disadvantage of CEA is that the policy 
objective is predetermined rather than arising from 
the analysis. CEA in itself is of no assistance in 
determining policy objectives. As has been noted 
by others, there is an assumption of CEA, rarely 
discussed, that the required additional resources 
need to be transferred from another health inter-
vention or other sources. 
A further extension of evaluation techniques 
comes in the form of cost-utility analysis (CUA). 
While CUA is the least common of the methods of 
economic evaluation identified, its use within the 
healthcare sector warrants some discussion. Cost 
utility analysis calculates the cost per specified 
health effect (of a program, a technology or a 
pharmacological intervention) and expresses out-
comes as uniform units of health. These units are 
presumed to have similar values across all condi-
tions. The health effects are weighted to reflect 
individual or societal preferences for different 
health outcomes. 
The most common weighting units are Quality 
Adjusted Life Years (QALYs) and Disability 
Adjusted Life Years (DALYs) (Murray and Lopez, 
1996). The QALY attempts to compare treatment 
priorities by identifying and measuring the utility 
of using resources to treat people of different 
health status, with different likely outcomes from 
treatment. A QALY is treated as a "Unit" of health 
which combines extension of life with a measure 
of its worth. Its use is particularly focussed on 
societal decisions relating to which good or service 
to produce relative to one another, i.e. allocative 
efficiency. There have been a number of "league 
tables" developed comparing QALY measures of 
quality and quantity of life years gained. For 
example it is thus possible to compare QALYS 
from resources spent on smoking cessation pro-
grams with resources spent on organ transplanta-
tion. 
The DALY is a measure which combines healthy 
life years lost because of premature mortality with 
healthy life years lost because of disability. This 
measure is a useful economic tool as the resource 
implications of each component of the DALY can 
be identified and estimated. The total loss of 
DALYs, worldwide, reflects the global burden of 
disease. 
CUA can be considered as a special form of cost-
effectiveness analysis, in which "effects" are mea-
sured in health status, and can contribute to soci-
etal decision-making in its identification of alloca-
tive efficiency. While it is still a matter contention 
whether QALYs and DALYs can be effective and 
acceptable public policy tools, they are increasingly 
being used to contribute to economic evaluation 
in the health care sector. 
Social benefit/cost analysis attempts to describe 
and quantify the social benefits and costs of a pol-
icy or program expressed in terms of a common 
monetary unit. The current value of the flow of 
social benefits over the life of a project is com-
pared with the current value of the flow of expen-
ditures which have yielded those benefits. 
Discounting techniques are used to permit com-
parison of the current values of differential flows 
over time of the benefits and expenditures. The 
costs and benefits, once valued in comparable 
terms, are then compared in terms of some criteri-
on -a benefit/cost ratio or some measure of the 
project's rate of return. 
Aggregate substance abuse cost exercises should 
identify and place values on all the costs of abuse 
of the substance under review. Any reduction of 
these costs due to the implementation of a partic-
ular program will represent benefits of that pro-
gram. Thus, the theoretical and practical issues 
involved in the valuation of program benefits 
should already have been faced in the substance 
abuse cost study. A human capital-based approach 
should provide all the necessary information, 
including discounted future costs. The demo-
graphic-based approach will not directly yield 
information about future substance abuse costs, so 
that extra analysis will be necessary. 
Aggregate abuse cost estimates should already 
have made the necessary distinctions between pri-
vate and social costs and should also have ensured 
that double counting of costs has been avoided by 
including only real (not pecuniary) costs. The esti-
mates should already have taken account of valu-
ation problems including the impact of private 
market imperfections, such as monopoly power or 
managed exchange rate regimes, and the difficul-
ties of placing valuations on intangibles such as 
pain, other forms of suffering and loss of life. (For 
a review of issues involved in estimating the costs 
of tobacco use see Lightwood, Collins, Lapsley 
and Novotny, 2000.) 
FIGURE 5 - INTERPRETATION OF SUBSTANCE ABUSE COST ESTIMATES 






Source: adapted from Collins and Lapsley (1998) 
Figure 5 presents a summary of the different types of costs which can be identified within a costing study, 
and the ways in which the results can be interpreted. The disaggregated costs provide essential tools for 
further types of economic evaluation including those identified in this chapter. 
s 
This document has presented proposed guidelines 
for estimating the economic costs associated with 
substance abuse. The purpose of these guidelines 
is to improve the validity and comparability of cost 
estimates in different societies. The development 
of improved cost estimates also offers the poten-
tial to develop more complete cost-benefit analy-
ses of policies and programmes aimed at reducing 
the harm associated with the use of psychoactive 
substances. 
A general framework has been proposed for the 
development of cost estimates. It has been argued 
that economic cost studies should be conducted 
within the framework of cost-of-illness studies. In 
cost estimation studies, the impact of substance 
abuse on the material welfare of a society is esti-
mated by examining the social costs of treatment, 
prevention, research, law enforcement and lost 
productivity plus some measure of the quality of 
life years lost. It is recognized that data are fre-
quently lacking for many of these costs. 
However, in many countries it will be possible to 
develop reasonable estimates for some, if not 
most, of the costs associated with substance 
abuse. Thus, these guidelines should be viewed as 
a framework rather than a rigorous methodology 
to be applied in every situation. 
An intriguing possibility is the development of spe-
cial "satellite accounts" in the System of National 
Accounts (SNA) to estimate the costs of substance 
abuse. In 1993 those concerned with defining the 
SNA framework issued a new manual, which 
included the concept of satellite accounts. 15 Its 
Chapter 11 sets down criteria for satellite analysis 
and accounts. Their initial concern is better repre-
senting the physical environment in the SNA, but 
they will also be used for characterizing the 
behaviour of non-market activities, such as house-
work. It would also seem a sensible development 
in COl studies in general, and those involving sub-
stance abuse in particular, to develop them in a 
satellite SNA account framework, as far as that is 
possible. 
Appendix A: 
Glossary of common 




Each discipline has its own terminology. In a 
growing interdisciplinary area as is the evaluation 
of substance abuse, such terminology, while nec-
essary, can be a hindrance. The following glossary 
is of terms which have come up in the course of 
the work thus far. The glossary is confined to 
terms used in the various papers and does not 
claim to be comprehensive, or to replace more 
extensive dictionaries of health economics. 
Wherever possible a standard dictionary term is 
used. Where there are a variety of definitions we 
have used the one which corresponds most close-
ly to that in the papers. 
In some cases where the term is relatively new 
and/or contentious, or will be unfamiliar to the 
non-specialist economist, there is some elabora-
tion of its meaning. We have clustered some com-
mon terms, often opposites, together so the read-
er can gain a better idea of the distinction or con-
trast that is being sought. Words in bold in the 
text have their own reference. 
Brian Easton and Robert Bowie 
abuse see use 
addiction & dependence 
can be treated as synonymous in the case of 
drugs/substances. Addiction is defined by Jacob 
and Fehr a "a state of dependence upon a drug 
substance which is harmful to physical or mental 
health, social wellbeing, and/or economic func-
tioning". This poses a problem for economists as 
to what extent the phenomenon involves irra-
tionality. 
aetiologic fraction or attributable fraction 
refers the proportion of cases of a disorder 
(cause of disease or death, or a particular type of 
crime) that can be causally attributed to a partic-
ular risk factor, such as drug misuse. 
avoidable costs & unavoidable costs 
In the context of cost-of-illness studies avoidable 
costs are those which could be avoided in the 
future if the appropriate treatment or policy 
were to be implemented. However some costs 
are the result of actions taken in the past, and 
are unavoidable, despite the new treatment or 
policy. If everyone stopped smoking, there 
would still be morbidity and mortality effects 
from the physiological damage of past smoking. 
The continuing costs of these would be unavoid-
able. Avoidability depends in part on the time 
period under consideration -the longer the time 
period, the greater the proportion of costs which 
are avoidable. 
benefit cost analysis see cost-benefit analysis 
benefits see costs 
budgetary impact studies estimate the economic 
costs and benefits of substance use and misuse 
to government budgets through its outlays and 
revenues. Care needs to be taken to clearly 
define "government", since it may refer to the 
national government only or include lower levels 
of government such as states and local authori-
ties. 
consensual crimes see victimless crimes 
consequences/causality/costs is a summary of the 
three-step process in the Harwood paper for the 
framework for cost-of-illness studies. The elabo-
ration is 
- identify the tangible consequences attribut-
able to substance abuse; 
-document causality between substance 
abuse and the consequences, and quantify 
frequency; 
- assign economic values. 
Maynard et al use a parallel identification/mea-
surement/valuation framework. 
consumer surplus is the difference between what 
consumers would be willing to pay for a good or 
service and the market price that they are actu-
ally required to pay. 
core & non-core. Core costs in relation to sub-
stance abuse are those which occur primarily 
within the domain of the health system, while 
non-core costs occur outside it. The public 
health sector is a part of the core, but so is the 
private health sector. See institutional arrange-
ments. 
cost-benefit, cost-effectiveness analyses, and cost 
utility analysis. Cost-benefit analysis (CBA), 
also known as benefit-cost analysis, involves the 
enumeration and evaluation in terms of a com-
mon unit, usually money, of all opportunity costs 
and benefits of taking a particular action. The 
costs and benefits are measured from the soci-
etal viewpoint, and usually ignore the distribu-
tion within the nation. If the benefit of an action 
exceeds the costs then there is a sense in which 
it is in the interests of the nation to take that 
course. Where there are costs and benefits 
occurring through time, the method involves dis-
counting. Cost-effectiveness analysis (CEA) is 
the procedure for identifying the least-cost 
means of pursuing a particular objective. For 
instance there may be two (or more) treatment 
alternatives. A CEA would evaluate which treat-
ment produced the given outcome using least 
resources. Cost utility analysis (CUA) calculates 
the cost per specified health effect (of a pro-
gram, a technology or a pharmaceutical inter-
vention) and expresses outcomes as uniform 
units of health. These units are presumed to 
have similar values across all conditions. 
cost-effectiveness analysis see cost-benefit analysis 
cost-of-illness analysis (COl) asks what are the 
total costs incurred by a particular illness. Since 
the cost measure is an opportunity cost, they in 
effect ask what would be the resources released 
to society if the illness did not exist. Thus the 
cost-of-illness is related to the benefits in a cost-
benefit analysis. The economic and social costs 
of substance abuse are a cost-of-illness analysis. 
costs, opportunity costs, historical costs, & bene-
fits. Opportunity cost is the value of a resource 
in its most highly valued alternative use. It is the 
concept economists use when valuing costs. 
They ask if a resource is not used for this pur-
pose what is its value in the next best purpose. 
In a competitive market in which all goods are 
traded and where there are no market imperfec-
tions, the opportunity cost of a resource is 
revealed by its market price. However these 
assumptions do not always hold, as when the 
resource is not bought and sold - it is non-mar-
ket. Sometimes payments which appear to a 
layperson to be costs are not opportunity costs, 
and are left out of the calculations or calculated 
in a different way. e.g. historical costs and trans-
fers. Historical costs reflect the past payments 
for a resource, but they may not represent the 
opportunity cost. If some medical equipment it is 
now useless, its opportunity cost is zero or the 
scrap value, while its historical cost is the cost of 
purchase, less depreciation. Benefits are the 
gains, before costs are deducted, of any particu-
lar course of action, preventive program, thera-
py, treatment, etc. They are usually valued in 
money terms. Ideally the valuation is willingness 
to pay. 
cost utility analysis see cost benefit analysis 
counterfactual propositions are the situation 
which the economist sets up as the alternative to 
the current one in order to assess the benefits 
and opportunity costs (e.g. for a cost-benefit 
analysis) of a different policy, treatment or cir-
cumstance. For instance the economist may be 
investigating the policy of raising taxes on alco-
hol, or of a new treatment regime for a narcotic, 
or the situation in which tobacco had never 
been available. Cost-of-illness studies have the 
counterfactual proposition that the illness does 
not occur. There may be more than one counter-
factual proposition to a situation, so the results 
may be very sensitive to the exact assumption. 
For instance, it could be argued that the coun-
terfactual to a situation without alcohol is 
greater use of narcotics. 
DALYs {disability adjusted life years) see QALYs 
demographic approach & human capital 
approach. The demographic approach (Collins 
and Lapsley, 1991) involves the counterfactual 
proposition of what would have occurred to the 
population if the illness (or whatever) had never 
occurred in the past. It is essentially a retrospec-
tive approach, and reflects a national account-
ing method. The human capital approach used 
extensively in cost-benefit analyses (Harwood, 
1994) involves tracing the future effects of the 
change in policy (or whatever) on the popula-
tion. Its counterfactual proposition is about what 
would happen if the illness ceased from the pre-
sent, and values future gains by discounting to 
the present. It is essentially a prospective 
approach. 
dependence see addiction 
direct costs & indirect costs. In health economics 
direct costs are usually the costs to the core health 
system. Indirect costs are those incurred else-
where, notably but not exclusively productivity 
lost. However elsewhere in economics the terms 
refer to variable costs and fixed costs respectively, 
and these (or other) definitions sometimes are 
used in health economics. 
disability adjusted life years (DALYs) see QALYs. 
discount rate see discounting 
discounting, discount rate, & present value 
Discounting is the procedure by which a flow of 
benefits or costs incurred or accruing at different 
points in time is expressed as an equivalent 
money sum at a single point in time, normally 
the present. It is especially important where 
there is an investment element to the activity. 
Discounting involves the use of a discount rate, 
which is difficult to measure or agree upon. In 
principle the discount rate is the rate of 
exchange between money sums at different 
times, in effect an interest rate. In the case 
where the sum is discounted back to the current 
date, it is called the present value. 
double counting, insurance. Double counting, the 
phenomenon where a resource is included in a 
total more than once, needs to be avoided. For 
example insurance spending has to be split into 
two components. The first is the actual cost of 
administering the scheme, the transaction cost. 
The second is the payment to the insured. This 
benefit is offset by the cost in the insurance pay-
ment. It would be double counting to include 
the insurance payment (except for the transac-
tion costs) such as for motor vehicle coverage, 
and also the cost incurred by the payment the 
insurance covered, such as the cost of car 
repairs. 
equilibrium. In the context of these studies, equi-
librium is the situation where there has been full 
adjustment to a changed external factor (often 
arising out of a difference in the counterfactual 
scenario). In partial equilibrium analysis, the 
changes only occur in an isolated part of the 
economy (usually a market) but do not impact 
significantly on an economy as a whole. This is 
the usual assumption in costs of substance abuse 
studies. However where the market or industry 
is sufficiently large and there are significant feed-
back effects on the economy as a whole, the 
analysis has to be based on a general equilibri-
um approach. Examples in substance abuse 
might involve a drug producing industry which 
was a sizeable part of the economy as a whole 
(or its export sector). 
external costs see internal costs 
general equilibrium see equilibrium 
gross costs & net costs. Gross costs consist of all 
costs, and ignore any offsetting benefits. If the 
benefits are deducted the remainder are net 
costs. In the event of a net cost being negative 
(i.e. benefits exceeding gross costs), there is a 
net benefit. 
GOP see gross domestic product 
GNP see gross domestic product 
gross national product see gross domestic product 
gross domestic product (GOP) is the total money 
value of all the final goods and services pro-
duced in the economy in a period (usually a 
year). Typically it covers only those activities 
which occur in the market (including the gov-
ernment sectors, although there are some minor 
exceptions. Gross nation product (GNP) is GDP 
plus the net property income from abroad. The 
fundamental distinction is that GDP covers the 
economic activities within a nation's boundaries, 
while GNP refers to the activities which the 
nation's people are involved with. They differ 
(but usually not by much in quantitative terms) 
because nationals own some production which 
occurs abroad, and some of the domestic (within 
national boundaries) production is owned by 
foreigners. The SNA and international agencies 
such as the OECD concentrate on GDP, but 
some countries, notably the USA pay more 
attention to GNP. 
human capital approach see demographic approach 
identification/measurement/valuation is the sum-
mary of the three step process used in costs of 
illness studies (Maynard et al., 1994). The elab-
oration is 
- which elements to include in the work; 
- how to measure the effects in each area 
over the relevant time period; 
- how to value these effects in a common unit 
of account. 
Harwood (1994) uses the parallel 
consequence/ causality I cost framework. 
illicit drugs & licit drugs. It is usually unlawful to 
possess or use illicit drugs, which typically 
include narcotics. Licit drugs are those whose 
use is generally lawful, and usually include alco-
hol and tobacco (although in some countries 
alcohol consumption is unlawful). Note that it is 
possible to misuse a licit drug, as occurs with 
some prescription drugs. 
incidence prevalence & point prevalence. 
Incidence is the number of instances of illness 
commencing, or of persons falling ill, during a 
given period for a population. It is about new 
events. Prevalence is the number of instances of 
a given disease or other condition in a given 
population at a designated time. If the period is 
not mentioned, the concept usually refers to the 
situation at a specified point in time, that is 
point prevalence. 
indirect costs see direct costs 
insurance (treatment of) see double counting 
intangible costs see tangible costs 
internal costs & external costs. Economists usually 
assume that individuals make decisions in their 
own interests. The costs and benefits taken into 
account are internalized while those which are 
ignored are external to the decision. These 
externalities occur when the individuals making 
decisions ignore the consequences of their deci-
sions for others. A complication is that while 
internal costs are private costs to the decision-
maker, some of the external costs may be pri-
vate costs to others. The complement of private 
cost in the context of these studies is social cost, 
some of which may be in the private sector. 
irrational see rational 
licit drugs see illicit drug 
marginal is the term economists use when they 
are considering the effects of one extra unit. 
Thus marginal cost is the additional costs from 
the extra unit, and marginal value is the extra 
value. If the marginal value exceeds the marginal 
cost it makes sense to use the unit, and to 
repeat this for the next unit until the net margin-
al gain is zero. 
marginal cost see marginal 
marginal value see marginal 
market & non-market. The point of this distinction 
is to observe that while many costs and benefits 
occur tangibly in the market others, of some-
times greater importance, occur outside it. This 
includes intangibles but also activities in the 
household and elsewhere such as carework and 
housework, which are not paid, but nevertheless 
involves the resource of labour effort (and which 
may be diverted from the market). 
morbidity is any subjective or objective departure 
from a state of physiological or psychological 
well-being. (Sickness, illness, and morbid condi-
tion are synonyms in this sense.) 
mortality refers to death. 
national accounts are a system of analysis the pro-
duction, distribution, expenditure, and financing 
of a nation. In recent years the international 
standards have been extended from a primary 
concern on market activities, to cover non-mar-
ket ones such as the environment and house-
work. Some features of cost-of-illness studies 
can be seen to be in a national accounting 
framework. 
net costs see gross costs 
opportunity costs see benefits 
partial equilibrium see equilibrium 
point prevalence see incidence 
present value see discounting 
prevalence see incidence 
private, public, and social costs. Private costs 
have two meanings in the economics literature. 
They may refer to the costs considered by the 
single private decision maker (internal costs), or 
they may refer to the costs of those in the pri-
vate sector, not carried by the public sector. As a 
rule public costs refer to costs in the public (i.e. 
government) sector. The complement of private 
costs in the first sense of the private decision 
maker is usually social costs. Because there is no 
uniformity of definition, the terms "public" and 
"private" should always be treated with care. 
productivity loss. As a result of illness a person 
may be less productive because of higher absen-
teeism or lower output on the job. This loss of 
production is included in the costs of illness. In 
principle loss of productivity should cover conse-
quences outside the market economy, such as 
reductions in human carework and housework 
by the sick person. 
project appraisal evaluates the efficiency of alter-
native projects or alternative policies. Its aims are 
to determine, by a process of enumeration of 
the benefits and costs of alternative projects or 
policies, the appropriate level of public resources 
to be devoted to the problem and the particular 
solutions to which those resources should be 
devoted. It helps to maximise the social rate of 
return resulting from the use of public resources 
by identifying the most efficient use for these 
resources. 
prospective & retrospective. A retrospective 
analysis typically involves a counterfactual 
proposition about an event which might have 
occurred in the past as it impacts on the situa-
tion today, whereas a prospective analysis asks 
about the effects of a counterfactual event with 
effects which begin at the point in time of the 
analysis (or shortly after) and with consequences 
into the future. 
public costs see private costs 
QALYs, or quality adjusted life years, sometimes 
used in CEAs, measure any years of life gained 
from a treatment adjusted for consequential 
changes in the quality of the life as the result of 
an improvement in the enjoyment of the years 
from reduced pain, increased mobility, and so 
forth. DALYs, or disability adjusted life years, 
are another way of measuring changes in the 
quality of life. 
quality adjusted life years see QALYs 
quantifiable & non-quantifiable. Many benefits 
and costs are directly quantifiable (or measur-
able), or can be indirectly quantified. However in 
the case of some of the most important- often 
social - ones, it is not possible to do so, and 
these are called non-quantifiable. Sometimes ad 
hoc methods are used to put estimates on non-
quantifiable costs, rather than leave them out of 
the evaluation altogether. 
rapid assessment methods are being developed by 
the WHO and other international agencies to 
enable data-poor countries to be able to make a 
broad assessment of the likely importance of a 
policy, or the need to gather more information, 
using data which are likely to be available but 
may not be comprehensive or particularly accu-
rate. 
rational, non-rational & irrational. Economics 
assumes that individuals are generally rational, 
pursuing their own best interests as best they 
can. ("Bounded" rationality recognizes they may 
not have the information, time, or best decision 
strategies to do so- that decision making 
involves costs.) Note that the internal decision 
may ignore the external costs to others. 
However the existence of addiction and drug 
abuse may suggest that sometimes individuals 
act irrationally, failing to pursue their own best 
interests, even in a bounded way. Collins and 
Lapsley explore this issue further in the section 
on addictive and non-addictive consumption. 
Their conclusion is that where drug consumption 
is irrational, the expenditure on the drugs is not 
a benefit to the individual and hence is a part of 
the total costs of abuse. 
risk factor refers to a characteristics of an individ-
ual or the environment which is associated with 
an increased risk of a particular disorder. 
retrospective see prospective 
SNA, the System of National Accounts, is the 
international standard for measuring GDP 
social costs see internal costs and private costs 
structural unemployment see workforce 
system of national accounts see SNA 
tangible & intangible. Tangible costs and benefits 
are those which can be easily measured in 
money terms. Intangible ones cannot be so easi-
ly measured, although it is often useful to make 
an attempt to do so (perhaps using a willing-
ness to pay approach). Very often the intangible 
costs involving changes in quality and length of 
life prove to be more important in the valuation 
than the tangible ones. 
transfers or transfer payments (such taxes, subsi-
dies, and welfare payments) do not relate to 
resource costs, so that the cost to one person is 
exactly offset by the benefit to someone else (as 
when somebody's tax is another's social security 
payment). It would be double counting to 
include the transfer payment as a cost, but not 
to offset the contribution. Again transaction 
costs may be relevant. 
transaction costs are those costs involved in a trans-
action. They include any costs for administering 
the transaction (e.g. the government and private 
compliance costs of the tax system), plus any loss-
es from behavioural responses (as when taxpayers 
reduce effort because of higher tax rates). The past 
practice has been to assume transaction costs may 
be neglected because they are small. They may not 
be. 
unavoidable costs see avoidable costs 
unemployment see workforce 
use & abuse. Economists tend not to judge the 
usefulness of the use of a product or substance 
to the user, other than in terms of the user's 
assessment. However the existence of addiction 
and irrational behaviour would seem to under-
mine that assumption. Other disciplines seem 
not to have a rigorous definition of abuse. A 
medical definition might be "drug abuse is 
deemed to occur when a relevant aetiologic 
fraction is greater than zero, i.e. when drug 
abuse adversely affects the health of the user". 
Economists tend to assume that a rational user 
takes this detriment into consideration when 
they are making the use decision. Sometimes the 
term is used pejoratively. Abel's Dictionary of 
Alcohol Use and Abuse (1985) remarks, no 
doubt ironically, that alcohol abuse is "consump-
tion to the point where it results in social disap-
proval", which is the sort of judgement that 
economists' try to avoid. Even so the term may 
be used as a short-hand for some longer con-
cept which is carefully defined. For instance 
Collins and Lapsley define the term in their 
paper as "when the use of a drug or substance 
imposes social [external] costs in addition to pri-
vate [internal] costs", and devote an entire sec-
tion to refining their definition. 
value of life recognises that the effect of a treat-
ment (or policy) may be to save lives, and that 
this effect should be included in a cost-benefit 
analysis. Otherwise the analysis would ignore 
life enhancing treatments, and comparisons 
would favour those which made no such com-
parisons. On the other hand the notion of 
putting a finite sum on the "value of life" might 
seem offensive. To put an infinite sum, however, 
would mean that there could be no trade-off for 
improvements in the quality of life. For example 
a CBA would be likely to favour a zero speed 
limit for cars if the value of life was infinite. The 
study's approach has favoured the replacement 
of a value of life concept with a social gains 
from additional life years. Whichever concept is 
used, it is difficult to get an agreed value for the 
item. A description of approaches for estimating 
the value of life will be found in the Maynard et 
al paper. 
value theory explains how prices are determined. 
("Value" was often used in the nineteenth cen-
tury as meaning long run prices). It is a central 
part of the modern economics paradigm and 
underpins the system of national accounting 
(SNA) and cost-benefit analysis. 
victimless crimes. Certain types of crime involve 
no apparent "victim" and are sometimes termed 
consensual or victimless crimes. These are activi-
ties such as sex for pay, illegal gambling and the 
illegal drug trade. In some nations it is not 
uncommon to find some drug dependent per-
sons in these professions. 
willingness to pay is a measure of benefit oppor-
tunity cost, especially where an intangible is 
involved. Measurement can involve polling indi-
viduals, asking what they would be prepared to 
pay for the resource or outcome. There is a 
growing body of empirical studies- such as 
using surveys- which attempt to measure the 
willingness to pay. 
workforce is the term used to cover that part of 
the labour force which is in active paid employ-
ment, and is not unemployed. While the con-
ventional division is between the labour force 
(which covers the workforce, and those who are 
unemployed) and not-in-the-labour force, only 
those employed in the workforce directly cause a 
loss of (market) production through a loss of 
employment effectiveness as a result of poorer 
health. The unemployed are those who are not 
employed but actively seeking paid employment. 
The structurally unemployed are those unem-
ployed who tend not have the skills demanded 
by employers. Thus if an employed person 
leaves the workforce (say through illness or 
death) the employer is unlikely to turn to a 
structurally unemployed person to fill the vacan-
cy. 
Appendix B: 




There are a handful of economies, and more 
regions, where the drug producing industries play 
a significant part in economic activity (sometimes 
in the informal economy). These pose particular 
problems for economic evaluation, insofar as the 
counterfactual scenario involves changes to the 
scale of production (and, the extreme case which 
is used here for illustrative purposes, even its clo-
sure), which are of significant size to impact on 
the structure of the economy. This appendix 
sketches those issues, by describing first how the 
production side is handled in the majority of eco-
nomic evaluations, where the drug producing 
industry is small (or non-existent), and then 
extending the analysis to where the industry is 
large, indicating differences arising in the technical 
treatment. 
It should be emphasized that the fundamental 
analysis is exactly the same for both cases. The 
differences arise because in the small industry case 
there are some acceptable simplifying analytic 
assumptions- in technical terms "partial equilibri-
um" analysis may be used instead of "general 
equilibrium" analysis. It should also be clear from 
the following account that there is no simple line 
between "large" and "small". The distinction is 
whether the simplifications are justified. This is 
usually a straightforward judgement in the case of 
whole economies, but may be more ambiguous in 
the case of regions. It should also be noted that 
the drug production industry may be functioning 
legally or illegally (usually depending upon 
whether its output is licit or illicit), which also 
affects the evaluation, as is discussed below. 
The distinctions of a drug producing industry 
being either large or small in the economy and of 
its activities being legal or illegal, generates a two 
by two table, as follows (with an example in each 
of the four countries). 
As always, the counterfactual assumption is crucial 
in setting out the cost evaluation. There is a wide 
range of possible scenarios which will reflect par-
ticular circumstances. For instance, the small-illegal 
counterfactual is likely to be a consequence of the 
assumption that local or national drug consump-
tion ends. In the case of the small-legal industry 
the elimination of local consumption is unlikely to 
end the industry and it will turn to (or increase) 
exporting (unless it is heavily protected and ineffi-
cient). The large-legal industry is probably already 
a major exporter and its closure or reduction in 
scale may reflect some international shift, which 
has nothing to do with changes in local consump-
tion. The possibilities of what might close down a 
large-illegal industry are varied, including a drop in 
world demand or effective supply control policies. 
The following discussion is based on a generic clo-
sure, but the particularities of the counterfactual 
may affect a specific estimate. 
Relatively small-scale production of legal drugs 
While a particular industry may be large in a 
region, this category covers those legal drug pro-
ducing industries that are small in relation to the 
national economy as a whole. There will be transi-
tion effects, but it is usually assumed that in the 
medium to long run following industry closure (or 
reduction in scale) the factors of production (e.g., 
land, labour and capital) will be redeployed to the 
same extent they had in the past (or perhaps that 
currently unemployed factors will take up in their 
place). Depending on the degree of mobility, it is 
possible that some factors (e.g. labour) may 
migrate to other regions (in which case the social 
cost of the industry in the region may differ from 
the economy as a whole). 
However, some of those production resources may 
be industry specific. This may apply most notably 
to land. The next best use of land currently used 
for drug production may be valued considerably 
less by the market. As far as measures of opportu-
nity cost are concerned, the social loss from the 
industry equals the reduction in the market return 
for those specific factors. It does not equal the 
total value of the production resource. For exam-
ple, suppose an industry was annually producing 
US$ 100 million worth of tobacco, and the next 
best alternative was potatoes with an output value 
of US$ 90 million. Then the social cost of closing 
the tobacco industry would be US$ 10 million per 
annum, not US$ 100 million per annum. 
It cannot be understated that it is quite wrong to 
describe the gross output of an industry as its 
social cost of closure. The statement applies only if 
none of the resources used in the small-scale legal 
drug production could be deployed in any other 
economic activity. The economic cost is the differ-
ence between the returns to the factors of produc-
tion of the industry and the returns to the next 
best option. This is a general economic proposition 
and does not just apply to drug producing indus-
tries. 
Note that the counterfactual scenario may entail a 
complicated story of other industries adjusting. It 
does not assume that smokers simply switch to 
buying potatoes. So the estimated social cost is 
the net effect. However, because the industry is 
small, it is unnecessary to trace the impact of its 
closure on the economy as a whole. As a general 
rule, the long-term industry-specific resources 
used in a small-scale legal drug industry will be 
land and possibly some labour skills. While some 
capital may be industry-specific in the short run 
(e.g. drying kilns for tobacco), in the long run it 
will depreciate and be replaced by some other 
capital (e.g. warehouses for sorting potatoes). 
The meaning of this estimate of the social cost of 
drug production is as follows. If the industry were 
to close down (or reduce in scale) there would be 
a loss of material welfare equal to the estimated 
social cost. However, this is in principle the same 
value as the loss of private consumer surplus if 
there is no excessive consumption. (In practice the 
two methods may treat second order effects dif-
ferently, and of course there will be estimation 
errors.) The relative balance between the social 
costs of production and changes in consumer sur-
plus arises because changes in production values 
are driven by changes in consumer values, and 
vice versa. It would be double counting to include 
the production and consumption losses in the 
aggregate, since they are two ways of measuring 
the same thing. 
Where there is excessive consumption, the 
methodology discounts the apparent market value 
to consumers of that consumption. Thus the pro-
duction value will exceed the estimated consump-
tion value. This means that the production is that 
much less value to the economy. Production val-
ues exceed the value that the consumers use in 
their voluntary decisions. Again it would be double 
counting to add the change in production values 
to the changes in consumer surplus. Moreover, 
where there is excessive consumption, it would be 
an overestimate to use the production values in 
place of consumer values. 
Relatively small-scale production of illegal drugs 
The measurement of the social costs for small-
scale illegal drug production will be similar to that 
for small-scale legal drug production, if the coun-
terfactual scenario is the same. However, there are 
two relatively minor differences when illicit drug 
production is involved. First, when small-scale ille-
gal drug production is curtailed, production 
resources may shift from the informal (unmea-
sured) economy to the formal measured one, and 
thus give a false impression of an increase in GDP. 
Attention should be drawn to any offsetting 
reduction in the informal economy. Second, 
depending on the precise assumptions, there may 
be a real gain to the economy if there is a reduc-
tion in policing and other related law enforcement 
costs. 
A major difference may be that the illegal industry 
is avoiding tax. Its closure and replacement by 
legitimate industries would increase the tax base. 
This is a benefit to the economy insofar as other 
taxes can be reduced and the burden of taxation 
reduced. 
The small-scale illegal drug production industry 
may also be associated with some corruption of 
the type we shall discuss in the large-illegal indus-
try. However, the magnitude will be small, the 
consequences less endemic, and the evaluation of 
the impact on production and the public sector 
manageable. 
This cost of closure is to be treated similarly to the 
similar estimates for the cost of closure for small-
legal industries. 
Relatively large-scale production of legal drugs 
The fundamental difference between a large and 
small industry is that the closure or severe curtail-
ment of a large industry could well have a marked 
impact on the economy as a whole, involving 
major adjustments. For instance, if an industry is a 
major exporter, if there is not any substantial 
external support such as international financial 
assistance and the next best use of production 
resources is much less remunerative, the closure of 
this industry would mean that the economy would 
experience a major loss of foreign exchange rev-
enue, the real exchange rate would fall, there 
would be a marked reduction in real incomes, and 
the response would be major structural change in 
the long run. Indeed, it is conceivable that closure 
could result in a major depression in the short run. 
Because of the size of the industry in the economy 
as a whole, it is not possible to use the special 
case of the "partial equilibrium" analysis underpin-
ning the small industry approach. It is not neces-
sary here to describe "general equilibrium" analy-
sis, which is a well-established procedure for 
examining the long run impact of- among other 
things- industry closure. The result will be to give 
an estimated value of GDP while the industry is 
functioning, and compare this to the estimated 
value of the GDP after the industry is closed down 
or reduced substantially in scale. The difference 
(after adjusting for price changes) is loss of social 
welfare, or the social cost of closure or scale 
reduction. Note that the data requirements for 
general equilibrium analysis are substantial -con-
siderably more than the national accounts which 
may be used for the partial equilibrium analysis. In 
practice many countries have insufficient data to 
use the technique. 
To understand the significance of the estimated 
social cost of industry closure using a general equi-
librium model, assume that there is zero local con-
sumption, so that all the production is exported. In 
this case the reduction in GDP represents the actu-
al loss of production and hence consumption and 
welfare to the country. This point also applies for a 
study from a regional perspective. (Insofar as there 
is a reduction in domestic consumption this needs 
to be allowed for in the interpretation). 
The loss of welfare of the large-scale production 
of legal drugs in a particular country is offset (sub-
ject to second order effects) by the gains to the 
other countries whose consumers desist or reduce 
excessive consumption (assuming that is the 
counterfactual scenario). Thus the overall gains 
and losses will depend very much on the geo-
graphic unit used in the analysis. Where this is 
matter of significance - typically a large industry in 
an open economy, a comprehensive evaluation of 
costs should include estimates of the burden of 
costs to the rest of the world. 
Relatively large-scale production of illegal drugs 
If the industry under consideration involves illegal 
activities, the measurement difficulties increase. 
Almost certainly the quality of the economic data 
base for illegal activities is lower than for legal 
activities, and often substantially so. Among the 
major difficulties are: 
The industry is poorly measured; 
the industry generates other transfers and trans-
actions which are poorly measured; 
where the industry interacts with the legal sys-
tem the prices of the transactions may be poorly 
measured; and 
the industry is often in a developing economy 
with a low per capita income which has a limited 
data base anyway (see Chapter 5). 
However, it is not only the lack of data for the 
general equilibrium model which limits the ability 
to calculation of social costs. Large illegal indus-
tries are almost certainly associated with pervasive 
and endemic corruption that it distorts civil society 
and good government. Among their effects are: 
The public sector is corrupted and functions 
inefficiently; 
there is institutional instability which generates 
commercial uncertainty and discourages legiti-
mate investment (including overseas develop-
ment investment) and encourages capital flight 
(including flight of highly trained human capital); 
enforcement, control, and elimination measures 
directed at the illicit drug production industry 
may have side effects such as environmental 
damage from attempted crop controls which 
entail significant costs to the local economy; 
market prices may be distorted from true reflect-
ing true social values; and 
there are costs to the economy from warring 
among the drug barons, and the drugs may 
maintain guerilla activities at a significant scale. 
The counterfactual scenario is that without this 
industry the country would experience a stable 
society and good governance. The various collat-
eral activities would not occur. 
In principle it is possible to characterize in quanti-
tative detail the society with and without the ille-
gal industry. In practice it does not seem possible 
to do this, in a reasonably rigorous way. 
It is likely that a general equilibrium analysis that 
focuses only on the production shifts- were it 
possible- would, as in the case of a large-scale 
legal drug production industry, show a decrease in 
material welfare if the large-scale illegal drug 
industry were closed or substantially scaled back. 
However, it is likely that the elimination of corrup-
tion in the governance of society would result in a 
net higher GOP. How much higher, we just do not 
know. The cost of closure for large-illegal indus-
tries seems appears likely to be negative (i.e., the 
net impact on GOP would be positive) but one 




costs of substance 
abuse to GOP 
In Section 3.8, it was noted that one cannot, 
strictly speaking, compare estimates of the costs of 
substance abuse to the Gross Domestic Product 
(GOP) because the former include both tangible 
and intangible costs while GDP is generally limited 
to tangible outputs of the economy. The purpose 
of this brief appendix is to describe how it is possi-
ble to make meaningful comparisons of any tangi-
ble measure. It is recommended any comparison 
should be in two parts: 
the tangible social costs of substance abuse 
which assess the consequential loss of material 
output can be compared with US$ GDP (the 
dollar sign being included to confirm the variable 
is measured in monetary units). If the value of 
the tangible material costs is US$ T then the 
ratio US$ T /US$ GDP measures the effective 
increase in material goods and services available 
if the substance abuse were eliminated (or what-
ever is involved in the counterfactual scenario). 
(Where the tangible social costs include non-
market production, the comparison is not quite 
consistent and either those non-market- but 
tangible- costs should be excluded, or GDP 
should be augmented by non-market produc-
tion. The former is easier). 
the intangible costs of substance abuse which 
assess the loss or deterioration of live above that 
of any material cost should be compared with 
the same measure applied to the population a 
whole. We illustrate the principle when QALYs 
are being used. Suppose the consequential loss 
in QALYs from substance abuse are equal IT 
quality life years. If the value of one QALY is 
determined to be US$ V, then the calculated loss 
will be US$ V x IT = US$ VIT (say). Suppose the 
total QALYs in the existing population is P. Then 
its value will be US$ V x P = US$ VP (say). (The 
calculation of P may not be easy, as it involves 
an estimation of the average QALY per person, 
which will be less than unity because there is 
disability within the population not caused by 
substance abuse). 
The ratio US$ VIT /US$ VP (or IT /P) measures the 
proportional increase in quality life years if there is 
no substance abuse (or whatever is the counter-
factual scenario). This easily understood ratio is a 
meaningful measure of the impact of substance 
abuse on the quality of life. (If the calculations are 
based on deaths caused by substance abuse, then 
the denominator is total population, and the ratio 
an indicator of how much larger the population 
would be were there no substance abuse). 
For comparison purposes then, we recommend 
that the social costs of substance abuse be pre-
sented as representing a US$ T /US$ GDP reduc-
tion in material welfare and an IT /P (= US$ 
VIT /US$ VP) reduction in quality life years. If an 
aggregate is required the sum US$ T + US$ VIT 
should be used, but it should NEVER be compared 
with GOP. 
This approach resolves the issue for those who 
have an ethical objection to valuing human life. 
They can still report the two proportions, but need 
not report the aggregate, noting that the ratio 
IT /P need not include a valuation of life but is sim-
ply a comparison of (adjusted) life years or lives. 
Since there is no internationally agreed procedure 
for measuring the intangible costs of life- in con-
trast to the well established, theoretically under-
pinned, internationally accepted measure GOP-
then international comparisons of the costs of sub-
stance abuse which involve valuing life (above 
that of its contribution to material production) are 
unclear. (While valuation methodologies vary it is 
not obvious how to compare dollar values 
between countries even when the valuation 
methodology- such as willingness-to-pay- is the 
same). 
Because the IT /P ratio is not dependent upon the 
dollar value of a human life (since it multiplies 
both the denominator and numerator) this helps 
resolve the problem of international comparisons. 
(It should be noted the ratio does not assume that 
a QALY or similar measure in country A has the 
same value as one in country B. At this stage in 
international comparisons it is probably useful to 
avoid such comparisons). 
Even so the ratio is likely to depend on whether 
the evaluation is in QALYs, DALYs, lives or other 
measure. Moreover some of the differences in the 
method for calculating quantitative magnitude 
(e.g. QALY vs. DALY) will cancel out between the 
top and bottom measures of the ratio. 
The comparison of tangible costs is relatively 
straightforward because the proportion of GDP is 
a useful (but, of course, incomplete) measure 
which is broadly comparable (although any rigor-
ous comparison requires comparable counterfactu-
al scenarios and similar methods of estimation). 
Meanwhile the IT /P ratio has some merits for 
intangible cost comparisons. It is not dependent 
upon the dollar value for human lives and some of 
the differences in method cancel out because the 
same method is applied to the numerator and 
denominator. 
We recommend this ratio as the best practical way 
of making international comparisons of the non-
material costs of substance abuse, until there is 
more international agreement on a procedure. 
However, it is unlikely that it will ever make sense 
to compare intangible costs with GDP. 
Appendix D: 
Application of the 
guidelines in cost 
estimation studies 
The purpose of this appendix is to briefly illustrate 
the practical application of these guidelines. Since 
the publication of the first edition of the 
International Guidelines for Estimating the Costs of 
Substance Abuse, the guidelines have been used 
in several COl studies. Among its principal aims, 
the guidelines are intended to enhance consensus 
on appropriate methodology and promote greater 
comparability regarding the results of studies in 
different countries. By agreement, the authors of 
the guidelines used the guidelines in subsequent 
COl studies conducted in Australia, Canada, New 
Zealand and the U.S. (Collins and Lapsley, 1995; 
Collins and Lapsley, 1998; Easton, 1998; Single et 
al., 1998; Harwood et al., 1999). 
In Australia the guidelines have been used in refin-
ing estimates of the social costs of drug abuse 
(alcohol, tobacco and illicit drugs) for 1992 
(Collins and Lapsley, 1995). They have also been 
used in estimating the social costs of smoking in 
these years in two Australian States, Victoria and 
Western Australia (Collins and Lapsley, 1998). A 
new study of Australian social costs in the financial 
year 1998/9, again using the guidelines, is due for 
completion in the northern Autumn 2002. In 
Canada a cost estimation study was completed in 
1996 utilizing the guidelines (Single et al., 1996; 
Single et al., 1998). The study is widely cited and 
used by policy makers and addictions specialists in 
Canada. A detailed description of data sources 
was published to assist future updating of the cost 
estimates (Choi et al., 1997). To address one of 
many research needs identified by the cost study, 
the Canadian Centre on Substance Abuse subse-
quently developed a special research project aimed 
at providing more exact estimates of the propor-
tion of crime attributable to alcohol and drug use 
in Canada (Pernanen et al., 2002). The guidelines 
were similarly the basis for cost estimation studies 
in New Zealand (Easton, 1997), the U.S. 
(Harwood et al., 1999) and the Czech Republic 
(Zabransky et al., 2001 ). The reader is referred to 
these studies for examples of how the methods 
discussed in these guidelines have been applied to 
generate estimates of the costs of substance 
abuse. 
While not every cost estimation study has made 
use of them, it is expected that the guidelines will 
be increasingly utilized in the future as a growing 
number of countries are considering or have 
decided to undertake cost estimation studies. The 
member states of the Inter-American Agency on 
Narcotic Drugs (CICAD), which includes all coun-
tries in the Western Hemisphere, have agreed to 
regularly monitor economic costs attributable to 
illicit drug misuse. CICAD is currently developing a 
training program based on the guidelines for esti-
mating the costs of illicit drugs and it is expected 
that pilot cost estimation studies will be initiated in 
the near future. Training seminars have already 
been conducted in Chile in 1999 sponsored by 
CICAD, as well as in Colombia in 2000. The 
guidelines are also being utilized in other parts of 
the world. For example, the revised guidelines 
reported in this document, incorporating greater 
attention to the problems of estimation in devel-
oping countries having less adequate data sources, 
are already being used as the basis for research 
projects on the social costs of smoking in several 
South East Asian countries, including Malaysia, 
Thailand and Cambodia. 
One of the primary purposes of this document is 
to assist researchers dealing with the many issues 
involved in estimating the economic costs of sub-
stance abuse and to thereby promote greater stan-
dardisation in methodology and improved compa-
rability of results. It is expected that there will be 
further refinements as the body of research litera-
ture on the costs of substance abuse continues to 
grow. Thus, these guidelines should be viewed as 
a work in progress, subject to continual updating 
and revision as methodological refinements and 
better information become available. 
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1 The papers presented were: David Collins and 
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Model"; Henrick Harwood, "Analytical Principles 
and Issues in Making Cost of Illness Estimates 
for Substance Abuse"; and Alan Maynard, 
Christine Godfrey and G. Hardman, "Conceptual 
Issues in Estimating the Social Costs of Alcohol". 
2 D.Collins & H.Lapsley, Estimating the Economic 
Costs of Drug Abuse in Australia, National cam-
paign Against Drug Abuse Monograph No.15, 
1991. 
3 Or Gross National Product (GNP) in the United 
States. 
4 Theoretical Issues in Abuse Cost Estimation, 
paper prepared after the symposium. 
5 Even so we ignore the effects of passive smok-
ing, in order to keep the story as simple as possi-
ble. 
6 Again the concept needs to be treated with care. 
Implicit in the counterfactual scenario is that the 
potential production from the greater productivi-
ty of the substance abuse is realised or, insofar 
that it is not, the potential is taken up in volun-
tary leisure with the same value as the additional 
production (and not involuntary unemploy-
ment). 
7 Pressed between the economic and policy logic, 
and cultural and religious or spiritual sensitivities, 
participants at the International Symposium on 
Estimating the Social and Economic Costs of 
Substance Abuse could not resolve the question 
of the treatment of the valuation of life. Instead 
it was suggested to use a deliberately clumsy 
term of social gains from additional (quality) 
life years. The term "social" is not meant to 
connote a gain in a religious sense, but to indi-
cate that society may (or may not) value any 
improvements in the quality of life as a result of 
reduction in substance abuse. In making this 
suggestion the proposers were aware they were 
putting the matter into a temporary limbo, 
rather than ultimately resolving the philosophical 
issue. That will depend upon a wider range of 
professions than even those at the symposium. 
After that resolution economists can turn to the 
question of the best valuation method, if any. In 
the interim a number of methods are advocated, 
their choice depending on the resolving the 
deeper philosophical issue. 
8 There is another variant of COl studies which 
might be considered a third approach. Manning 
and his colleagues (1991 ), in contrast to the 
studies by Dorothy Rice (Rice, 1966; Rice et al., 
1985; Rice et al., 1986; Rice et al., 1990; Rice et 
al., 1991; Rice, 1993), strictly limits cost esti-
mates to external costs (paid by others). 
Furthermore, Manning's external cost approach 
is incidence-based and utilizes a lifetime model 
of use. Thus the cost-benefit totals represent the 
current value of present and future substance 
use. 
9 Assuming that it had done so in the past. 
10 Over time the unavoidable costs diminish, so 
that the CBA counterfactual scenario has a 
growing stream of cost savings from the smok-
ing cessation. Typically these are discounted to 
give a present value of the avoided costs. 
Discounting amounts to summing together all 
those costs, but the further a cost is in the 
future, the less weight it is given, because it is 
generally taken that income and spending in the 
future is less valuable than the same activity in 
the present. Typically the weighting involves a 
discount rate, whose magnitude is a matter of 
contention among economists, although there is 
widespread agreement that the concept is cor-
rect in principle. It follows that not only should 
the costs of medical care be estimated through 
time, discounting them to a present value, but 
so should other costs such as productivity and 
mortality losses. 
11 A common difference is that the treatment the 
evaluator is looking at, may reduce but not elim-
inate the illness, so only a proportion of the COl 
items will be relevant. Sometimes the proportion 
will differ from item to item. 
12 According to Benson et al. (1992:690), "drug 
use may cause crime among a subset of about 
15 to 25% of the drug-using population but 
there are other plausible reasons for the appar-
ent correlation between property crime and drug 
use". A study to determine the aetiologic frac-
tion of property and violent crime that may be 
causally attributed to illicit drug use is currently 
underway under the auspices of the Canadian 
Centre on Substance Abuse. 
13 The anti-drug prevention is often general and 
then is not a direct concern of the drug budgets. 
For example, a campaign actualising the healthy 
life for the youth is not directly labelled "drug" 
and cannot then be charged to the drug budget. 
Only the campaigns which directly targeted drug 
enter the budget. The sums spent in this way are 
uneasy to calculate and of little importance in 
the sight of the repression and health expenses. 
14 This approach accordingly does not address the 
conceptual issues associated with any enjoyment 
or benefit that consumers derive from use of 
psychoactive substances. Nor does this approach 
deal with the fact that resources used to address 
the problems of psychoactive substances are cre-
ating new jobs- actually different jobs, since the 
funds are taken away from other uses that 
would themselves create jobs. Also, the theoreti-
cal economic constructs of "consumer's sur-
plus", marginal utility analysis, and social welfare 
functions are beyond the scope of this analysis. 
15 System of National Accounts: 1993, published 
by Commission of the European Communities 
(Union), International Bank for Reconstruction 
and Development ("World Bank"). International 
Monetary Fund, Organization for Economic 
Cooperation and Development, and the United 
Nations. 
16 Because the SNA framework involves a set of 
subsidiary tables- the most important for these 
purposes are the household, public, producer, 
and (perhaps) rest-of-world sectors- it may be 
useful to split the COl estimate into these com-
ponents. It makes sense to separate out an 
account for the drug users from the household 
account, and it will be as useful to separate the 
production activities of the drug suppliers out 
from the producer account. Fully elaborated, 
there will be interaction between the subsidiary 
tables, as when the taxes paid by the user (if 
any) will be payments in the private user 
account, and a receipt in the public sector 
account. Ideally the accounts could be set out so 
their net balance is equal to the COl. 
17 This glossary was written by Brian Easton and 
Robert Bowie for the first edition of these guide-
lines, with some additional terms drafted by Eric 
Single. The authors are grateful to David Collins 
and Helen Lapsley for a comment on an earlier 
draft, but take full responsibility for any errors 
and omissions. 
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